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Pyruvate kinase catalyses the final step in glycolysis and is responsible for net ATP 
production. There are four pyruvate kinase isoforms expressed in humans; LPYK, RPYK, 
M1PYK and M2PYK. The allosteric enzyme M2PYK plays an important role in cancer 
cell metabolism and is subject to complex regulation by numerous naturally occurring 
small-molecule metabolites. Post-translational modifications have also been found to play 
a key role in the regulation of M2PYK, among these cysteine oxidation. This thesis 
describes the production and characterisation of M2PYK cysteine point mutants in order 
to investigate the mechanism of regulation by cysteine modification. 
From a total of ten cysteines present in M2PYK, five were chosen for mutation based on 
a combination of the results from the cysteine oxidation prediction program (COPP) web 
interface and published experimental evidence for cysteine modification of M2PYK. 
Eight point mutants of these five cysteines were produced and characterised. Low 
resolution gel filtration of all the mutants shows that mutation of these cysteines has an 
effect on tetramer:dimer:monomer equilibrium of M2PYK suggesting that cysteine 
modifications could regulate M2PYK activity by affecting oligomeric state. Activity 
assays show that none of the cysteine point mutations are sufficient to protect M2PYK 
from oxidation by H2O2 indicating that more than one cysteine is involved in the 
regulation of M2PYK by oxidation. 
Nitric oxide (NO) imbalance has recently emerged as playing a key role in numerous 
diseases including cancer. NO regulates the function of target proteins through the 
addition of a nitroso moiety from NO-derived metabolites to a reactive cysteine, a 
process known as protein S-nitrosylation. M2PYK has been found to be S-nitrosylated in 
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vivo. Using the biotin-switch assay in vitro combined with mass spectrometry I have 
shown that a likely candidate for the target of S-nitrosylation of M2PYK is C326.   
This thesis also describes the structures of two cysteine point mutants; M2PYK C424A 
and M2PYK C358S. The structures show that these mutations have very little effect on 
the overall conformation of M2PYK with only very subtle localised changes. The 
structure of the mutant M2PYK C358S shows some interesting features including 
varying occupation of the active site resulting in differing conformations of the B 
domains within the same tetramer, and an unusual B factor distribution which could be 
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Chapter 1: Pyruvate Kinase 
 
1.1: Structure and function of pyruvate kinase 
 
1.1.1 The role of pyruvate kinase in cellular metabolism 
Pyruvate kinase (PYK) catalyses the final step of glycolysis, the conversion of 
phosphoenolpyruvate (PEP) and ADP into pyruvate and ATP (Figure 1.1). The product 
pyruvate is used by several metabolic pathways, thus placing PYK at an important 
metabolic intersection [1] (Figure 1.1). Additionally PYK is responsible for net ATP 
production in the glycolytic pathway which, in contrast to mitochondrial respiration, is 
independent of oxygen supply thus allowing for cell survival under hypoxic conditions 
[2]. 
Historically it has been stated that PYK is a key regulatory enzyme of glycolysis that, 
together with phosphofructokinase (PFK) and hexokinase, controls the flux through the 
glycolytic pathway in almost every cell type [3]. This statement is based on the belief that 
the steps of a biochemical pathway that control the flux are those that catalyse the 
reactions with large negative ΔG° values (thermodynamic approach) and have the lowest 
maximal rates (kinetic approach) [4]. However, these approaches yield qualitative results 
and assume that the “key” steps have full control of the pathway. In reality, the situation 
appears to be much more complex. It was hypothesized that over-expression of one or a 
few key glycolytic enzymes should increase the flux through the glycolytic pathway of 
Saccharomyces cerevisiae. However, when advances in genetic engineering allowed for 
this hypothesis to be tested experimentally it was discovered that the presumed limiting 
enzymes, when over-expressed individually or in combination, had very little to no effect 
on the steady state flux through the pathway in S. cerevisiae [5]–[9](reviewed in [4]). 
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This has also been shown to be the case in other organisms including Escherichia coli 
[10], [11], Lactococcus lactis [12], Aspergillus niger [13], and Chinese hamster ovary 
[14] (reviewed in [4]).   
In addition, computational modeling based on kinetics data obtained for individual 
enzymes has been used to study the control of glycolysis in Trypanosoma brucei. It was 
found that control appeared to shift between the glucose transporter on the one hand, and 
aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase and 
glycerol-3-phosphate dehydrogenase combined on the other, depending on the exact 
experimental parameters [15]. 
In summary, it is no longer valid to assume that PYK is one of the few key regulatory 
enzymes that control the flux through the glycolytic pathway. In reality it is likely that its 
role in controlling flux is more subtle and is combined with the regulatory effects of 
many or all of the other glycolytic enzymes, including the glucose transporter. 
 
1.1.2 Pyruvate kinase isoforms in humans 
There are four pyruvate kinase isoforms expressed in humans; LPYK, RPYK, M1PYK 
and M2PYK. LPYK is found in tissues where gluconeogenesis is carried out, primarily in 
liver, but also in kidney and intestine [16]. Its expression is regulated by diet; a 
carbohydrate-rich diet increases LPYK expression whereas hunger reduces it [2]. LPYK 
provides key regulation for maintaining the balance between gluconeogenesis and 
glycolysis in the liver and is therefore under investigation as an antihyperglycemic target 
in diabetics. RPYK is exclusively found in erythrocytes and is very similar to LPYK, 
both enzymes being expressed by the same gene under the control of different tissue-
specific promoters [17]. Erythrocytes rely exclusively on glycolysis for their ATP 
production and are thus heavily dependent on RPYK for survival.  Deficiency of RPYK 
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leads to ATP depletion and ultimately hemolysis and it is one of the most common causes 
of nonspherocytic hemolytic anaemia in humans. M1PYK is a highly active, non 
allosteric isoform that is expressed in tissues where large amounts of energy need to be 
produced rapidly, such as brain and muscle [2]. M2PYK is expressed in all proliferating 
cells and is a tightly controlled allosteric enzyme. M1PYK and M2PYK are splice 
variants of the same gene, the alternatively spliced exon consisting of 56 residues of 




Gene products Physiological location Allostery
PKLR
LPYK Liver Yes
RPYK Red blood cells Yes
PKM
M1PYK Skeletal muscle, heart, brain No
M2PYK





















Figure 1.1 Pyruvate kinase (PYK) catalyses the final step of the glycolytic pathway. 
PYK catalyses the reaction between PEP and ADP producing ATP and pyruvate. 
Pyruvate feeds in to multiple metabolic pathways so PYK is at an important metabolic 
intersection. There are two PYK genes found in mammals, PKLR and PKM, from which 




1.1.3 Regulation of pyruvate kinase isoform expression 
Human pyruvate kinase is encoded by two genes, PKLR and PKM, which result in 
expression of 4 protein products (Figure 1.1). The PKLR gene produces LPYK and 
RPYK by way of alternative promoters; in liver, kidney and intestine transcription starts 
from the second exon, whereas in erythrocytes it is initiated from the first exon with the 
second exon being spliced out as an intron [19](Figure 1.2). The PKM gene produces 
M1PYK and M2PYK by mutually exclusive alternative splicing; exons 9 and 10 are 
specific to M1- and M2PYK respectively while all other exons are common to both 
isoforms [18](Figure 1.2). It has been found that, in cancer cells, expression of 
heterogeneous nuclear ribonucleoproteins (hNRP1 and hNRP2) and polypyrimidine tract 
binding protein (PTB) is upregulated by c-Myc, and that these proteins bind to sequences 
flanking exon 9 to hinder its transcription, resulting in inclusion of exon 10 [20][21]. 
 
1.1.4 The architecture of human pyruvate kinases 
Human pyruvate kinase is generally a homotetrameric enzyme which is made up of 
monomers of 58-62 kDa, depending upon the isoform (Figure 1.5). The PYK monomer is 
made up four domains: the N-terminal domain, A-, B-, and C-domains (Figure 1.4). The 
effector site is situated within the C-domain and is about 40 Å from the active site, which 
is located in the A-domain (Figure 1.5). The tetramer is held together by reciprocal 
hydrogen bonds across the C-C or ‘small’ interface, between neighbouring C-domains, 















M1PYK mRNA M2PYK mRNA
LPYK mRNA
 
Figure 1.2 Illustration of the expression of the mammalian pyruvate kinase isoforms 
(Diagram from [19]).  
A. LPYK and RPYK are produced from the same gene by use of tissue-specific 





























































Figure 1.3 Multiple sequence alignment of human pyruvate kinase isoforms.  
Regions resulting from the different exons included are highlighted. Colour scheme has 
been chosen to correspond to Figure 1.2. PKL exon 1 product = yellow, PKL exon 2 








10 20 30 40 50 60 70
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMN
80 90 100 110 120 130 140
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
VARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATL
150 160 170 180 190 200 210
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
KITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVN
220 230 240 250 260 270 280
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
LPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRF
290 300 310 320 330 340 350
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
DEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVAN
360 370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEAS
430 440 450 460 470 480 490
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
FKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRV




Figure 1.4 Architecture of M2PYK monomer.   
Structural representation of M2PYK monomer with protein sequence below coloured to 











Figure 1.5 Architecture of the M2 pyruvate kinase tetramer.  
Chain A has been coloured to help to identify the different domains; N (cyan = residues 
1-25), A (red = residues 25-116 and 220-402), B (blue = blue = residues 117-219), and C 
(yellow = residues 403-531)..  The large (A-A) and small (C-C) interfaces are indicated 




1.2: Allosteric regulation of pyruvate kinase   
 
1.2.1 Differences between M1- and M2PYK 
The result of mutually exclusive splicing of the PKM gene is that M1- and M2PYK differ 
in 22 residues within a 56 residue region situated at the C-C interface close to the F-1,6-
BP binding site (Figure 1.6)[18]. These differences alone allow for M2PYK to be in an 
allosterically regulated tetramer:dimer:monomer equilibrium while M1PYK is held in a 
constitutively active tetrameric state [22][23][24]. Comparison of the crystal structures of  
M1PYK and M2PYK bound to ATP, oxalate and F-1,6-BP shows an overall r.m.s fit of 
~0.5 Å with the only significant difference being seen in the splice variant region [22]. 
Specifically there are important differences in the hydrogen bonding involving Lys422 
(Figure 1.6). In M1PYK a tight clasp is formed the Cα1 and Cα2 helices around Lys422, 
which interacts with Glu409 via a salt bridge and forms hydrogen bonds with Ser402, 
Ser405 and Tyr444 [22]. In M2PYK, the Cα1 and Cα2 helices are pushed further apart by 
2.5 Å due to a difference in the backbone of the linker between the two helices thus 
resulting in relaxation of the tight “peg-in-hole” conformation observed in M1PYK [22]. 
This model has been validated using M2PYK point mutants and double mutants in which 
the M2PYK residues have been mutated to the M1PYK equivalent residues in the splice 
variant region. Specifically, work carried out during my MSc project showed that the 
three residues P403, P408 and T409 play an important role in determining the ability of 
M2PYK to dissociate. The double mutants P403S/P408L and P408L/T409M result in 
M2PYK that is tetrameric even in the absence of effector and substrates (unpublished 
data). This supports a model in which P403 and P408 play a role in holding the two α-
helices apart thereby relaxing the “clamp” around K422 from the neighbouring chain. 
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In addition, a point mutation of K422 to glutamate in M2PYK was also studied in order 
to investigate the importance of this residue in the oligomerisation of M2PYK. It was 
found that this mutation almost completely prevented tetramerisation (unpublished data). 
This was the expected outcome based on the model because the change in charge would 
prevent the formation of the salt bridges that hold the tetramer together across the C-C 
interface (Figure 1.6).  
 
1.2.2 The relationship between M2PYK oligomeric state and activity 
M2PYK exists in a concentration-dependent tetramer:dimer:monomer equilibrium with a 
Kd for tetramer dissociation of around 8 µM [22]. The tetramer:dimer:monomer 
equilibrium requires a long time to stabilize and M2PYK dissociates into monomers that 
are inactive at sub Kd concentrations [22]. In the presence of F-1,6-BP M2PYK 
monomers re-associate into active tetramers, a characteristic of V-type allosteric 
regulation [22]. M2PYK can also exist as an inactive T-state tetramer when bound to the 





















































Figure 1.6 Differences between M1- and 2PYK (adapted from [22]).  
A. M1PYK and M2PYK tetramers superimposed; M1PYK = blue, M2PYK = green B. 
Enlarged view of the splice variant region indicated in A showing an alignment of M1- 
and M2PYK structures with important side-chains shown. Significant differences are 
shown with numbered orange arrows: (1)In M1PYK, M409 repels Q440 which is no 
longer able to form a hydrogen bond with E410. (2) E410 is able to form a salt bridge 
with K422 from the neighbouring chain in M1PYK stabilising the dimer interface. (3) 
Cα2 of M2PYK is 2.5Å further from K422 than Cα2 of M1PYK due to the presence of 
two proline residues (P403 and P408) that act like a clamp to hold Cα1 and Cα2 apart in 








1.2.3 The regulation of M2PYK by small molecules 
M2PYK activity has been found to be influenced by more than 30 naturally occurring 
metabolites including amino acids, nucleotides, and intermediates of the glycolytic 
pathway, tricarboxylic acid cycle and pentose phosphate pathway [22]. This study was 
the first of its kind to test the effects of such a large number of naturally occurring small 
molecules on pyruvate kinase activity. The activities of M1PYK and M2PYK were 
measured in the presence of 58 naturally occurring metabolites selected from the 
glycolytic, tricarboxylic acid cycle and pentose phosphate pathways as well as other 
potential PYK modulators (amino acids, oxalic acid, tartaric acid and triiodo-L-thyronine 
(T3)) [22]. After expressing activity as a percentage deviation from that of the WT 
enzyme in the absence of modulator, ligands were defined as inhibiting if activity was 
less than 75% and activating if activity was more than 125% of that of WT enzyme in the 
absence of modulator [22]. Seventeen inhibitors were identified for M2PYK including 
the previously described inhibitors phenylalanine and thyroid hormone triiodo-L-
threonine (T3), but also tryptophan, alanine, oxalic acid, and ribose-5-phosphate [22]. 
Phenylalanine and alanine have also been identified as inhibitors of M2PYK in rat and 
mouse [25][26][27]. In addition, tryptophan has been found to be an inhibitor of rat 
M2PYK [27]. Only phenylalanine, oxalic acid and oxaloacetic acid were identified as 
weak inhibitors of M1PYK [22]. M2PYK was also found to have fourteen activators with 
F-1,6-BP, histidine and serine being the strongest, whereas no activators were identified 
for M1PYK [22]. F-1,6-BP is a well known allosteric activator of pyruvate kinase in 
many organisms from bacteria to mammals [28][29][25][30]. Histidine and serine have 
thus far only been identified as pyruvate kinase activators in human. Complex regulation 
by a wide range of naturally occurring small molecules allows M2PYK to act as a 
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nutrient sensor for the proliferating cell, a role that is discussed in more detail in section 
1.3.2.  
 
1.2.4 The regulation of M2PYK by post-translational modifications 
M2PYK has been found to be regulated by acetylation [31], phosphorylation [32], proline 
hydroxylation [33], and cysteine oxidation [34]. Protein acetylation involves the 
reversible addition of an acetyl group (CH3CO) to the terminal amine of lysine residues. 
It was first studied in relation to histone acetylation decades ago but recently there has 
been increased interest in enzymatic acetylation of other proteins as it is emerging as a 
widely used post-translational modification involved in regulating diverse cellular 
processes [35]. It has been found that the majority of metabolic proteins are acetylated 
and that this modification affects enzyme activity [36]. An interesting observation was 
that the concentration of extracellular nutrients had an influence on the acetylation of 
metabolic proteins indicating that acetylation could be involved in regulating metabolism 
based on extracellular cues [36]. M2PYK has been reported to be acetylated on lysine 
K305 leading to inhibition of enzyme activity and promoting lysosome-dependent 
degradation of M2PYK [37].  
Protein phosphorylation is catalysed by protein kinases which covalently attach a 
phosphate group to serine, threonine, or tyrosine residues of proteins. This form of post-
translational modification has been studied in detail as it is a commonly used 
modification in cell signalling pathways. In particular, tyrosine kinase signalling is often 
increased in tumours due to overexpression of cell surface growth factor receptors with 
tyrosine kinase activity within their cytoplasmic domains [38]. Furthermore, there is 
believed to be a link between tyrosine kinase signalling and cellular metabolism [38]. 
M2PYK has been reported to be phosphorylated on tyrosine Y105 by the oncogenic 
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tyrosine kinase FGFR1 (Fibroblast growth factor receptor 1) resulting in inhibition of 
M2PYK activity [39]. 
Proline hydroxylation is the most frequent post-translational modification found in 
humans and results in the formation of (2S,4R)-4-hydroxyproline (Hyp), an irreversible 
modification [40]. Hyp is well known for its role in stabilising the collagen triple helix 
[41] but has been found to be involved in a wide range of cellular processes [40]. It has 
recently been demonstrated that M2PYK can be hydroxylated on prolines P403 and P408 
and that this modification enhances its binding to and activation of HIF-1α (Hypoxia 
Inducible Factor 1α [33].  
More recently it has been discovered that cysteine oxidation also plays a role in 
regulating M2PYK activity [34]. Although an M2PYK monomer contains 10 cysteines, it 
was found that mutation of one cysteine (C358) to serine was enough to protect M2PYK 
from the effects of oxidation [34]. The regulation of M2PYK by cysteine oxidation is the 
main focus of this thesis and is discussed in more detail in section 1.3.5 and chapters 3 
and 4.  
 
1.2.5 The regulation of M2PYK by protein-protein interactions 
The role of protein-protein interactions in the regulation of M2PYK is very poorly 
characterised due to the difficulty in studying these weak interactions. However, evidence 
has been found for specific M2PYK binding partners which include HPV E7 (Human 
Papilloma virus E7) [42], HIF-1 [33], and the peptide hormone somatostatin [43].  
M2PYK has been found to be directly targeted by the E7 oncogene of human 
papillomavirus (HPV) leading to dissociation of the enzyme and its inhibition [42], [44]. 
Activation of hypoxia inducible factor 1 (HIF-1) commonly occurs in human cancers and 
leads to a switch from oxidative to glycolytic metabolism [45]. HIF-1 is a transcription 
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factor consisting of two subunits; HIF-1α and HIF-1β. HIF-1α expression is O2 regulated 
while HIF-1β is constitutively expressed [46]. The HIF-1 dimer binds to the hypoxia 
response element (HRE) of target genes, which includes the MPYK gene. M2PYK has 
recently been found to be a co-activator of HIF-1 [33]. 
M2PYK also interacts with the peptide hormone somatostatin and this interaction has 
been found to result in translocation of M2PYK into the nucleus and subsequent cell 




















Table 1.1 Summary of M2PYK mutants discussed in this thesis. a= Jakub Nowak MSc 
rotation project report, b= Rosie Palmer (Mitchell) MSc rotation project report, c= 
chapter 3, d= chapter 4. Numbers in brackets are the corresponding M2PYK WT values 






































































































































































































n/a n/a n/a n/a n/a n/a [49] 
C31A Cysteine oxidation n/a n/a n/a n/a n/a n/a c 






















C423S Cysteine oxidation n/a n/a n/a n/a n/a n/a c 











C424S Cysteine oxidation n/a n/a n/a n/a n/a n/a c 
C424L Cysteine oxidation n/a n/a n/a n/a n/a n/a c 




1.3 The relevance of studying the regulation of M2PYK activity 
 
1.3.1 The Warburg effect and M2PYK 
The Warburg effect is the name given to the observation made by Otto Warburg that 
cancer cells almost exclusively produce their energy from a high rate of glycolysis 
followed by production of lactic acid in the cytosol even in the presence of oxygen, a 
process that has been called “aerobic glycolysis” [50](Figure 1.7). This is in contrast to a 
comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria 
which is observed in most differentiated tissue (Figure 1.7). Warburg’s hypothesis was 
that cancer cells develop mitochondrial defects, leading to impaired oxidative 
phosphorylation and reliance on glycolytic metabolism for energy [50]. However, more 
recent work has shown that most cancers do not have impaired mitochondrial function. It 
has been suggested that cancer cells have a preference to use glucose to support cell 
growth rather than for oxidative phosphorylation [51]. The glycolytic gene set, including 
pyruvate kinase, has been found to be one of the most up regulated in tumours and 
expression of the M2PYK isoform has been shown to be necessary for aerobic glycolysis 
[51][52]. Switching pyruvate kinase expression in human cancer cell lines from M2PYK 
to the M1PYK isoform results in a reversal of the Warburg effect demonstrated by 
decreased lactate production and an increase in oxygen consumption [51].  
The dependence of cancer cells on glycolysis is currently being exploited in drug 
discovery programmes. For example, small molecule activators of M2PYK TEPP-46, 
DASA-58 and ML-265 are at preclinical stages of development, having been tested in 
lung cancer cell lines [53]. The rationale for using activators of M2PYK is to prevent the 
use of glycolytic intermediates for biosynthetic processes thereby inhibiting the 
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proliferation of cancer cells (See section 1.3.2). Another glycolytic enzyme that is being 
targeted for drug development is PGAM1, the inhibition of which should reduce 
glycolytic flux while at the same time compromising biosynthetic pathways due to the 
regulatory functions of its substrate and product on key metabolic enzymes [53]. Two 
small molecule inhibitors of PGAM1 are currently in drug development programmes at 
the preclinical stage; MJE3 and PGMI-004A. One of these, PGMI-004, has been shown 





Differentiated tissue Proliferating tissue/tumour












Figure 1.7 Schematic of the differences between oxidative phosphorylation, 
anaerobic glycolysis and aerobic glycolysis (Warburg effect) (adapted from [55]).  
In differentiated tissue, most of the pyruvate from glycolysis is completely oxidised in the 
mitochondria to produce CO2 in the process called oxidative phosphorylation. When 
oxygen is limiting, pyruvate is normally converted to lactate thus allowing glycolysis to 
continue by cycling NADH back to NAD. This process is called anaerobic glycolysis. In 
aerobic glycolysis, also known as the Warburg effect, most glucose (~85%) is converted 
to lactate regardless of whether there is oxygen present or not, and even though 
mitochondria remain functional. The 10% of glucose unaccounted for in the diagram is 








1.3.2 Regulation of M2PYK allows for cell proliferation 
Expression of the allosterically regulated pyruvate kinase isozyme M2PYK in cancer 
cells is an important regulator of the flow of glucose metabolites through the glycolytic 
pathway [2](Figure 1.8A). When M2PYK is active, glucose is converted to pyruvate and 
lactate producing ATP and recycling NAD+ for the glyceraldehyde 3-phosphate reaction 
of glycolysis [2]. In the case that M2PYK is inactivated, the glycolytic intermediates 
preceding it build up and can be used for synthetic processes allowing for cell 
proliferation [2] )(Figure 1.8A). For example, synthesis of the amino acids serine, 
glycine, and cysteine uses glycerate 3-phosphate as a precursor [2] (Figure 1.8A). 
Dihydroxyacetone phosphate is a precursor for the synthesis of phospholipids. The 
pentose-phosphate pathway that utilises glucose-6-phosphate leads to production of 
ribose-5-phosphate, a precursor of nucleotides [2] (1.8A). All of these molecules are 
essential for cells with a high proliferation rate. Furthermore, expression of M1PYK in 
human cancer cells in which M2PYK expression has been knocked down results in a 
reduced ability to form tumours in nude mouse xenografts [51](Figure 1.8B).  Therefore, 
it is likely that tight regulation of M2PYK activity provides a means of controlling the 






























Figure 1.8 Inhibition of M2PYK allows for accumulation of glycolytic intermediates 
that can be used for cell proliferation.  
A. Representation of the glycolytic pathway showing the intermediates that are used by 
the cell for proliferation and the essential building blocks that are synthesised from each 
of these intermediates. B. Nude mice were injected with M1 rescue H1299 cells on the 
left flank and M2 rescue H1299 cells on the right flank and then tumours dissected out 
[51]. The only three tumours that grew with M1PYK were much smaller than the 




1.3.3 Naturally occurring M2PYK polymorphisms and cancer  
The COSMIC database (Catalogue Of Somatic Mutations In Cancer) is an online 
database of somatically acquired mutations in human cancer that curates data from 
published literature as well as large-scale experimental screens. The COSMIC database 
reports 32 missense mutations in the MPYK gene coding for M2PYK. However, the 
presence of a mutation does not prove that it contributes to the cancer phenotype and 
none of these reported M2PYK mutations have been biochemically characterised. The 
database therefore presents a useful resource for the further study of the importance of 
M2PYK polymorphisms in cancer.   
There are only two published missense mutations of M2PYK that have been studied in 
detail, H391Y and K422R [47][48]. These were found in a patient with Bloom syndrome, 
a rare autosomal recessive disorder which results in many health problems including 
increased risk of cancer. This particular patient was prone to various types of cancer at an 
early age [47]. The mutation K422R is found at the C-C interface and H391Y is very 
close to the C-C interface. Both of these mutants were found to be less active than the 
wild-type M2PYK to different extents (Table 1.1). The K422R mutation had the most 
pronounced effect on activity which may be caused by stabilising the enzyme in a less 
active T-state tetramer conformation [48]. The H391Y mutation caused loss of 
cooperativity and allosteric behaviour evidenced by a shift of the typical sigmoidal curve, 
usually seen for M2PYK activity in the absence of F-1,6-BP, to a hyperbolic curve [48].  
Jakub Nowak, an MSc student in this laboratory, studied the effect of nine naturally 
occurring M2PYK polymorphisms on the oligomeric state and activity of the enzyme. 
The results showed that several of these naturally occurring mutations (Q310P, V392L, 
I103Y and V132L/I103Y) resulted in monomeric M2PYK that was inactive even in the 
presence of the allosteric activator F-1,6-BP (Table 1.1). None of these mutations have 
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been associated with higher risk of cancer, however it seems likely that they could play a 
role in cancer progression given that less active M2PYK would allow for more cell 
proliferation due to accumulation of glycolytic intermediates (Figure 1.8A). 
 
1.3.4 Reactive oxygen species (ROS) in cancer 
Proliferation resulting from stimulation by growth factors in normal cells requires ROS 
signalling. It has been proposed that ROS enhances proliferation through inhibition of 
phosphotyrosine kinases and PTEN (phosphatase and tensin homolog) leading to an 
increase in signalling through the tyrosine kinase and phosphatidylinositol-3 kinase (PI-
3K) pathways [56].  In cancer cells, abnormally high concentrations of ROS are produced 
as a result of mutations in tumour suppressor and oncogenic pathways, as well as 
conditions that often result from tumorigenesis such as hypoxia, matrix detachment, 
mitochondrial dysfunction and inflammation [57]–[66]. Cancer cells must therefore have 
mechanisms to maintain  the subtle ROS balance that allows sufficient proliferation while 
preventing potentially lethals ROS levels[62]. It has been found that cancer cells 
overexpress thioredoxin reductase-1 (TR1), a member of the thioredoxin antioxidant 
system [67]. This system is translocated to the nucleus in response to oxidative stress, 
where it maintains the reducing environment necessary for transcription factor binding to 
DNA and gene expression [68]. It is probable that the increase in thioredoxin expression 

























Figure 1.9 Control of M2PYK by oxidation could contribute to regulating Reactive 
Oxygen Species (ROS) in proliferating cells.  
The proposed mechanism [34] is as follows. Cysteine oxidation causes M2PYK to 
become more monomeric which makes it inactive. The glycolytic intermediates earlier in 
the pathway build up as PEP is no longer converted to pyruvate by M2PYK. Glucose 6-
phosphate enters the Pentose Phosphate Pathway (PPP) where it contributes to the 
production of NADPH. NAPDH is used by Glutathione Reductase (GR) to produce 
reduced GSH from GSSG. Increase in GSH causes a decrease in ROS, which in turn 
could lead to reversal of M2PYK cysteine oxidation thus allowing it to reassociate into its 








1.3.5 Regulation of M2PYK by ROS 
Oxidation has been found to inhibit a range of pyruvate kinase orthologues including E. 
coli, yeast and human [69]–[71]. A study carried out in A549 human lung cancer cells 
found that an increase in intracellular ROS concentrations lead to decreased M2PYK 
activity [34]. This inhibition was reversed after treatment of cells lysates with the 
reducing agent dithiothreitol (DTT) [34]. It was proposed that oxidation of M2PYK leads 
to dissociation of the homotetramer, a conclusion based on the fact that treatment of 
human lung cancer cells expressing FLAG-tagged M2PYK with the oxidising agent 
diamide prevented tagged M2PYK co-immunoprecipitating with endogenous M2PYK 
[34]. The significance of this for the cancer cells is explained by the authors in a model, 
illustrated in figure 1.9, in which the regulation of M2PYK by redox potential of the cell 
allows cancer cells to sustain antioxidant responses [34]. The idea is that inhibition of 
M2PYK would lead to accumulation of the glycolytic intermediate glucose-6-phosphate 
which would then enter the pentose phosphate pathway (PPP) thereby producing NADPH 
(Figure 1.9). NADPH is used by glutathione reductase (GR) to produce the reducing 
agent GSH from the oxidised GSSG (Figure 1.9). GSH reacts with ROS thereby 
decreasing the oxidising potential of the cell and allowing oxidation of M2PYK to be 
reversed,  leading to re-activation of the enzyme (Figure 1.9).  
In this same paper it was proposed that there is one cysteine in M2PYK, Cys358, that is 
primarily responsible for its regulation by oxidation. However, given that there are 10 
cysteines in M2PYK and that many of them are accessible to solvent this hypothesis 
seems unlikely. The results presented in this thesis suggest that the situation is actually 




Chapter 2: Materials and Methods 
 
2.1 Cloning, PYK expression and purification 
 
2.1.1 Cloning of M2PYK mutants 
Mutants of M2PYK were made using the Quikchange site-directed mutagenesis kit 
(Stratagene) using pET28a-M2PYK as a template and following the instructions in the 
manual. The following mutants were generated: C31A, C326S, C358A, C358S, C423S, 
C424A, C424S and C424L. Mutations were confirmed by sequencing. 
 
2.1.2 Expression of human M PYKs in E.coli 
The following procedure was used to express M2PYK WT, M1PYK WT, and all 
M2PYK mutants except M2PYK C326S. Mutated plasmids were transformed into 
chemically competent BL21 E. coli cells (Novagen). Single colonies were used to 
inoculate 50ml LB media containing 50µg/ml kanamycin and incubated at 37°C 
overnight with shaking. 10ml was taken from each of the overnight cultures and used to 
inoculate 1L 2XTY media containing 50µg/ml kanamycin. 1L cultures were grown to an 
OD600 of 0.8 at 37°C with shaking. Cultures were incubated at 4ºC for 20 minutes before 
inducing expression by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 1mM and incubating at 20°C for 18 hours with shaking.  Cells were 
harvested in a JLA-9.1000 rotor at 8,000 rpm for 20 minutes at 10ºC. 1L cell pellets were 
flash frozen in liquid nitrogen before being stored at -80ºC. 
For expression of M2PYK C326S the mutated plasmid was transformed into chemically 
competent BL21 star E. coli cells (Novagen). A single colony was used to inoculate 50ml 
28 
 
LB media containing 50µg/ml kanamycin and incubated at 37ºC overnight with shaking. 
10ml was taken from the overnight cultures and used to inoculate 1L LB media 
containing 50µg/ml kanamycin. This 1L culture was grown to an OD600 of 0.6-0.8 at 
37ºC with shaking. IPTG was added to a final concentration of 1mM to induce expression 
and the culture was incubated at 18ºC for 3 hours with shaking. Cells were harvested in a 
JLA-9.1000 rotor at 8,000 rpm for 20 minutes at 10ºC. 1L cell pellets were flash frozen in 
liquid nitrogen before being stored at -80ºC. 
 
2.1.3 Preparation of cell lysates 
All purification steps were carried out at 4ºC unless otherwise stated. Cell pellets from 1 
litre cell culture were resuspended in 30ml lysis buffer (50mM NaH2PO4, 300mM NaCl, 
20mM imidazole, pH8.0, with EDTA free protease inhibitors (Roche)). Cells were lysed 
using a constant cell disruption system with pressure set to 25 MPa. The cell lysate was 
centrifuged at 22,000rpm for 45 minutes at 10ºC and the supernatant filtered using a 0.2 
µm syringe filter.  
 
2.1.4 Purification of bacterially expressed M PYKs 
Clarified cell lysate was loaded onto a 5ml IMAC hitrap HP sepharose column pre-
charged with cobalt at 2 ml/min. The flow rate was maintained at 2 ml/min for the 
duration of the affinity purification step. The column was washed with 10 column 
volumes (CV) of buffer A (50mM NaH2PO4, 300mM NaCl, 20mM imidazole, pH8.0) 
followed by an additional wash step with 15 CVs of 20% buffer B (50mM NaH2PO4, 
300mM NaCl, 250mM imidazole, pH8.0) to wash off contaminating proteins. The His-
tagged MPYK protein was eluted using a 5 CV step gradient of 100% buffer B. Eluted 
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fractions were pooled and loaded onto a superdex 200 26/60 XK gel filtration column 
pre-equilibrated with Dulbecco’s phosphate buffered saline without calcium and 
magnesium (PBS-CM – Sigma Cat. No. D5652). A flow rate of 2.5 ml/min was used 
throughout the gel filtration process. Eluted fractions were pooled and concentrated using 
a vivaspin column with molecular weight cut-off of 30 kDa. 
 
2.1.5 Measurement of protein concentration 
Protein concentration was determined by measuring absorbance at 280nm using a 





. Protein solutions were diluted to ensure the absorbance reading was 
always between 0.l and 1. Concentrations were measured 5 times to ensure consistency 
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Figure 2.1 Chromatograms showing standard traces for M PYK purification with 
SDS-PAGE gels.  
A. IMAC elution profile for M2PYK C31A with SDS-PAGE gel (inset) showing 
M2PYK protein at the expected size of about 60 kDa. B. Gel filtration elution profile for 
M2PYK C31A showing two peaks probably corresponding to tetramer (1) and monomer 
(3). There is probably also a small amount of dimeric form at the position labeled with 2, 
although the resolution of the column does not allow a peak to be distinguished. SDS-





2.2 Enzyme assays 
 
2.2.1 Measuring PYK activity using the LDH-coupled assay 
5ml protein solutions of 0.0025mg/ml M PYK were prepared by dilution in PBS-CM 
with or without addition of additives. The protein solutions were incubated at room 
temperature for 3 hours to ensure oligomeric equilibrium was reached.  
Meanwhile 25ml 2x Assay buffer was made (PBS-CM, 20mM MgCl2, 200mM KCl, 
4mM ADP, 1mM NADH, 30 U/ml LDH). 5ml of 2x Assay buffer was taken and PEP 
added to a concentration of 10mM. Two-fold serial dilutions of PEP were prepared in a 
96 well master block (Greiner Bio-one Cat. No. 780270) using 2x Assay buffer for 
dilution yielding PEP concentrations ranging from 78 µM to 10 mM (final assay 
concentrations 39 µM to 5 mM). A multi-channel pipette was used to transfer 50 µl of 
each PEP dilution to a column of a 96 well plate (Greiner Bio-one Cat. No. 655101). 
The reaction (Figure 2.2) was started by adding 50 µl protein solution to the PEP 
titrations in the 96 well plate using a multi-channel pipette. Final concentrations of 
reagents were as follows: 0.00125mg/ml M PYK, 10 mM MgCl2, 100 mM KCl. 2 mM 
ADP, 15 U/ml LDH, 0.5 mM NADH, and PEP concentrations ranging from 39 µM to 5 
mM. 
Plates were agitated for 10 seconds before measuring the decrease in absorbance at 340 
nm for 5 minutes using a plate reader (SpectraMax M5 multimode plate reader, 
Molecular Devices). Initial reaction rates were obtained using the SoftMax Pro software. 




2.2.2 Measuring PYK activity using Kinase Glo assay 
5ml protein solutions of 0.0025mg/ml M PYK were prepared by dilution in PBS-CM. 
Two samples were prepared for each protein; one with 10µM H2O2 and one with 1mM 
DTT. The protein solutions were incubated at room temperature for 3 hours to ensure 
oligomeric equilibrium was reached.  
Meanwhile 25ml 2x Assay buffer was made (PBS-CM, 20mM MgCl2, 200mM KCl, 
4mM ADP). 5ml of 2x Assay buffer was taken and PEP added to a concentration of 
2mM. A multi-channel pipette was used to transfer 25µl of 2mM PEP solution to the 
wells of a 96-well plate (Greiner Bio-one Cat. No. 655101).  
The reaction (Figure 2.3a) was started by adding 25µl protein solution to the PEP 
solution in the 96-well plate using a multi-channel pipette. The final concentrations of the 
reagents were as follows: 0.00125mg/ml M PYK, 10 mM MgCl2, 100 mM KCl. 2 mM 
ADP, and 1mM PEP.  The reaction was incubated for 30 minutes before adding 50µl 
Kinase Glo Plus reagent (Promega) was added to each well using a multi-channel pipette 
and the reaction (Figure 2.3b) incubated at room temperature in the dark for 10 minutes. 
End point luminescence readings were measured using a SpectraMax M5 multimode 





2.3 Biophysical assays 
 
2.3.1 Dynamic light scattering 
Dynamic light scattering (DLS), also known as Photon Correlation Spectroscopy (PCS) 
and Quasi-elastic light scattering (QELS), is a technique used for measuring the size 
distribution of particles in solution.  A laser beam is directed through a solution and is 
scattered in all directions when it meets a particle. The scattered light energy is detected 
on a photon detector.  
Particles in solution have a Brownian motion which causes laser light to be scattered in a 
time-dependent manner. These fluctuations can be used to derive the velocity of the 
Brownian motion allowing calculation of the particle size using the Stokes-Einstein 
relationship. 
A Zetasizer Auto Plate Sampler was used for DLS measurements of M2PYK mutants. 
50µl of M2PYK mutant (1mg/ml) was placed in one well of a 384-well plate. As a 
reference, the light scattering of PBS-CM (Sigma) only was measured. Samples were 
measured in a 12 μl quartz cell. 
  
2.3.2 Thermal shift assay 
The thermal shift assay takes advantage of the change in the fluorescence signal of 
SYPRO Orange dye when it comes into contact with a hydrophobic surface to monitor a 
protein undergoing thermal unfolding. A protein sample is subjected to incremental 
increases in temperature and the fluorescence signal monitored throughout the process. 
An increase in fluorescence signal indicates that the protein is unfolding and from this 
information a melting temperature can be deduced. The SYPRO Orange dye is supplied 
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by Invitrogen (catalogue no. S6650) at 5000x concentration in DMSO, and was diluted in 
PBS-CM before use. Test samples were prepared in a 96-well PCR plate (BioRad) before 
adding SYPRO Orange dye and sealing the plate with optical quality tape (BioRad). Each 
50 µl sample contained 0.55 mg/ml protein in PBS-CM with 1.11mM F-1,6-BP, 1mM 
H2O2, or 1mM DTT. The 96-well plate was heated in an i-Cycler iQ5 real-time PCR 
detection system (BioRad) from 20 to 80 ºC in increments of 1 ºC. A charge-coupled 
(CCD) camera was used to monitor the fluorescence changes in the wells simultaneously 
using an excitation wavelength of 485nm and an emission wavelength of 575nm. 
 
2.3.3 Analytical size exclusion chromatography 
Analytical size-exclusion chromatography was carried out as described by Morgan et al. 
[22]. MPYK protein samples were incubated overnight at room temperature at 0.1mg/ml 
before loading independently onto a Superdex 200 PC 3.2/30 gel filtration column pre-
equilibrated in PBS-CM at room temperature. A 25µl loop was used and 50 µl was 
injected at a rate of 0.1 ml/min. The column flow rate was maintained at 0.1 ml/min. UV 




2.4 Biotin-switch assay 
 
2.4.1 In vitro biotin-switch assay 
In vitro biotin switch assay was performed essentially as described by Jaffrey and Snyder 
[72] (Figure 2.2).  Protein samples were prepared by diluting to a concentration of 
1mg/ml in HEN buffer (250mM HEPES-NaOH, pH7.7, 1mM EDTA, 0.1mM 
Neocuproine). CysNO was used as the NO donor and was prepared by mixing 10µl 
100mM L-Cysteine with 10µl 100mM NaNO2 resulting in 50mM solution of CysNO 
which was diluted to 10mM with HEN buffer. CysNO was added to protein samples and 
the reaction incubated in the dark for 20 minutes. CysNO donor was removed by passing 
the samples through pre-equilibrated zeba-spin columns. MMTS blocking buffer (HEN 
buffer, 2.5% SDS, 20mM MMTS) was added to block unmodified cysteines and the 
reaction incubated at 50ºC for 20 minutes. 2 volumes of -20ºC acetone were then added 
and the samples incubated at -20ºC for 2 hours. Precipitated protein was pelleted by 
centrifuging at 14,000xg for 15 minutes. Supernatant was removed and residual acetone 
allowed to evaporate by placing tubes uncapped in a 37ºC incubator. Protein pellets were 
resuspended in 50µl HENS buffer (HEN buffer with 1% SDS). Biotin-labeling solution 
(4.5mM ascorbate, 1mM Biotin-HPDP) was added and the samples were incubated at 
4ºC overnight before running on two SDS-PAGE gels. One of the gels was stained with 
coomassie stain and the other was used for western blot with anti-biotin-HRP antibody 
























Figure 2.2 Biotin-switch assay workflow.  
Protein samples are nitrosylated using a nitrosylating agent such as CysNO followed by 
removal of nitrosylating agent using a desalt column. Free cysteines that are not 
nitrosylated are then blocked by reaction with methylmethanethiosulfonate (MMTS) in 
denaturing conditions (50˚C). Residual MMTS is then removed by precipitating protein 
with acetone and collecting the protein pellet. Ascorbate is then added to remove NO 
group from nitrosylated cysteines before labeling with biotin-HPDP. Protein samples are 





2.4.2 Mass spectrometry of biotinylated protein 
2.4.2.1 Sample Digestion 
The coomassie stained SDS-PAGE gel of biotin-switch assay samples was used to obtain 
samples for mass spectrometry analysis to identify biotinylated peptides. Prominent 
protein bands of the expected size for M PYK were excised from lanes corresponding to 
samples for M1PYK with and without CysNO treatment and M2PYK with and without 
CysNO treatment. In-gel digestion was similar to the protocol published in Nature by 
Schevchenko and colleagues [73]. DTT and iodoacetamide were not used to avoid 
reduction and alkylation of the peptides. Gel pieces were incubated in 300µl of 200mM 
ammonium bicarbonate (ABC) in 50% acetonitrile (ACN) at room temperature for 30 
minutes to remove SDS. This was followed by 3 washes with 500µl 20mM ABC in 50% 
ACN. The washed gel pieces were then covered with 100% ACN for about 5 minutes, 
ACN was removed and gel pieces allowed to air dry. Trypsin (29µl 50mM ABC + 1µl 
0.4µg/µg trypsin) was then added to the dehydrated gel pieces at 4ºC. The gel pieces 
were left to swell at 4ºC for a few minutes before transferring the tubes to 32ºC and 
incubating overnight.Samples were cleaned on ziptip, dried under low pressure 
(Speedvac from Thermo Jouan) and stored at -20 ºC. The dried peptide aliquots  were re-
suspended in 7µl Buffer A (2.5%v/v acetonitrile, 0.1%v/v formic acid in water) and were 








2.4.2.2 LC-MS analysis 
Nano-HPLC-MS/MS analysis was performed using an on-line system consisting of a 
nano-pump (Dionex Ultimate 3000, Thermo-Fisher, UK) coupled to a QExactive 
instrument (Thermo-Fisher, UK) with a pre-column of 300 µm x 5 mm (Acclaim 
Pepmap, 5 µm particle size) connected to a column of 75 µm x 50 cm (Acclaim Pepmap, 
3 µm particle size). Samples were analyzed on a 2 hour gradient in data dependent 
analysis (1 survey scan at 70k resolution followed by the top 5 MS/MS at 17.5k 
resolution). 
 
2.4.2.3 Label free quantitation  
Progenesis (Nonlinear Dynamics, UK) was used for LC-MS label-free quantitation. Only 
MS/MS peaks with a charge of 2+, 3+ or 4+ were taken into account for the total number 
of ‘Feature’ (signal at one particular retention time and m/z) and only the five most 
intense spectra per ‘Feature’ were considered in the analysis. Normalization was first 
performed based on the sum of the ion intensities of these sets of multi-charged ions (2+, 
3+, and 4+). The associated unique peptide ion intensities for a specific protein were then 
summed to generate an abundance value. The abundance was then transformed using an 
ArcSinH function (a log transform is not ideal considering the significant amount of near 
zero measurements generated by the current method of detection). Based on the 
abundance values, within group means were calculated and from there the fold changes 
(in comparison to control) were evaluated. One-way ANOVA was used to calculate the 





2.4.2.4 Protein identification 
Data from MS/MS spectra was searched using MASCOT Versions 2.4 (Matrix Science 
Ltd, UK) against an in-house database with maximum missed-cut value set to 2 and  
assuming trypsin cleavage. The following features were used in all searches: i) variable 
methionine oxidation, ii) cysteine  either blocked with methylthio or HDPD-biotin, iii) 
precursor mass tolerance of 10 ppm, iv) MS/MS tolerance of 0.05 amu, v) significance 




2.5 X-ray crystallography 
 
2.5.1 Crystallisation screening procedures 
Purified M2PYK C358A, M2PYK C358S and M2PYK C424A samples that had been 
stored at -80ºC were used for the experiments. Proteins were thawed on ice before mixing 
with ligands. Crystallisation experiments were carried out by the vapour diffusion method 
and the hanging drop technique at 18ºC (M2PYK C358A and M2PYK C424A) or 4ºC 
(M2PYK C358S).  
Crystallisation conditions were based on those used by Morgan et al. [22]. The drops 
were set up by mixing 1.5 µl of well solution with 1.5 µl of 10 mg/ml protein sample 
containing 5mM of each ligand. The well solution consisted of 6-16% PEG 3350, 
100mM sodium cacodylate (pH 6), 20 mM Triethanolamine-HCl buffer (pH 7.2), 50 mM 
MgCl2, 100mM KCl. Table 2.1 shows the procedure for setting up the well solutions. 
The drops were equilibrated against 1ml of well solution. 
 
Table 2.1 Procedure for preparation of well solutions used for crystallization. 1x metals 
buffer was prepared from a 10x metals buffer stock: 200mM TEA, pH7.2, 500mM 
MgCl2, 1M KCl. All solutions were filtered using a 0.2µm syringe filter before use.  
 
Stock solutions 
Final concentration of PEG 3350 (%) 
6 8 10 12 14 16 
40% PEG 3350 150 µl 200 µl 250 µl 300 µl 350 µl 400 µl 
1M Sodium cacodylate pH6.0 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
1x metals buffer 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
H2O 650 µl 600 µl 550 µl 500 µl 450 µl 400 µl 






2.5.2 Data collection and processing 
X-ray intensity data from crystals were collected at the Diamond synchrotron radiation 
facility in Oxfordshire, United Kingdom on beamline IO2. Prior to data collection 
crystals were equilibrated over a well solution containing a high concentration of PEG-
3350 to help dehydrate the crystal and eliminate the appearance of ice-rings. The 
intensity data were collected from single crystals flash frozen in liquid nitrogen at 100K. 
Processing was carried out by the Xia2 automated data reduction system 
 
2.5.3 Model building and refinement 
The M2PYK C358S structure was solved by molecular replacement using MolRep using 
the AC domains of the M2PYK structure with PDB ID 3SRH [74]. Because the B 
domains of the M2PYK C358S structure have very poor density they were solved 
separately. One of the B domains was found by using a B domain of M2PYK 3SRH 
separately in MolRep refinement. The other three B domains were placed by finding the 
corresponding B domains in the rabbit M2PYK structure with PDB ID 1PKN. The 
structure was then refined using REFMAC5 [75]. 
The M2PYK C424A structure was solved by molecular replacement using MolRep [74]. 
The M2PYK structure with PDB ID 3SRD was used as the search model because the two 









3.1.1 M2PYK is regulated by oxidation 
Oxidation has been found to inhibit a range of pyruvate kinase orthologues including E. 
coli, yeast and human [69]–[71]. A study carried out in A549 human lung cancer cells 
found that an increase in intracellular ROS concentrations lead to decreased M2PYK 
activity [34]. This inhibition was reversed after treatment of cells lysates with the 
reducing agent dithiothreitol (DTT) [34]. It was proposed that oxidation of M2PYK leads 
to dissociation of the homotetramer, a conclusion based on the fact that treatment of 
human lung cancer cells expressing FLAG-tagged M2PYK with the oxidising agent 
diamide prevented tagged M2PYK co-immunoprecipitating with endogenous M2PYK 
[34]. 
 
3.1.2 The possible role of M2PYK in regulating ROS in proliferating cells 
Expression of the allosterically regulated M2PYK in cancer cells is an important 
regulator of the flow of glucose metabolites through the glycolytic pathway [2]. Tight 
regulation of M2PYK activity provides a means of controlling the balance between 
energy production and synthetic processes that stem from the glycolytic pathway [2]. One 
of these synthetic processes is the pentose phophate pathway (PPP). The PPP produces 
the precursor to nucleic acid synthesis ribose-5-phosphate while also generating NADPH 
which is used by glutathione reductase to maintain GSH antioxidant levels in the cell 
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[76]. It is therefore concievable that expression of M2PYK could play an important role 























Figure 3.1 Control of M2PYK by oxidation could contribute to regulating Reactive 
Oxygen Species (ROS) in proliferating cells.  
The proposed mechanism [34] is as follows. Cysteine oxidation causes M2PYK to 
become more monomeric which makes it inactive. The glycolytic intermediates earlier in 
the pathway build up as PEP is no longer converted to pyruvate by M2PYK. Glucose 6-
phosphate enters the Pentose Phosphate Pathway (PPP) where it contributes to the 
production of NADPH. NAPDH is used by Glutathione Reductase (GR) to produce 
reduced GSH from GSSG. Increase in GSH causes a decrease in ROS, which in turn 
could lead to reversal of M2PYK cysteine oxidation thus allowing it to reassociate into its 




3.1.3 M2PYK contains ten cysteine residues 
Ten cysteines are found in the sequence of M2PYK (1.9%) (Figure 3.2). A cysteine 
content of 1.9%  is about average for a mammalian intracellular protein, which has been 
calculated to be 1.6±0.9% [77].  Many of the cysteines of M2PYK are readily accessible 
to solvent and thus modification by oxidising agents, suggesting that regulation of 
M2PYK by oxidation may be complex and involve multiple cysteines. However, it has 
been suggested that there is one cysteine, cysteine 358, that is primarily responsible for 
the regulation of M2PYK by oxidation [34]. This cysteine is situated in the β barrel close 
to the active site and its buried location makes it a surprising candidate for oxidation 
(Figure 3.2). The aim of this study was to investigate the claim that Cys358 is primarily 
responsible for the regulation of M2PYK by oxidation. To this end, M2PYK point 
mutants have been made and their behaviours in vitro have been studied.  
 
3.1.4 Which cysteine(s) of M2PYK are involved in its regulation by oxidation? 
In order to study the role of cysteine oxidation in the regulation of M2PYK, cysteine 
point mutations were made. The cysteines mutated were chosen based on the results of 
the cysteine oxidation prediction program (COPP) web interface [78]. The M2PYK 
structure 1T5A was used as the input for this program which identifies cysteines 
susceptible to oxidation based on proximity to nearest cysteine sulphur atom, solvent 
accessibility, and pKa [78]. The Cysteine Oxidation Prediction Algorithm is based on a 
database of the physicochemical properties of 161 oxidation-susceptible cysteines and 
161 oxidation-non-susceptible cysteines taken from a total of 100 polypeptides, called the 
balanced oxidation susceptible cysteine thiol database (BALOSCTdb). The program is 
capable of correctly classifying about 80% of cysteines, with 77.8% of cysteines from 
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transferases being correctly classified [78]. The BALOSCTdb is heavily biased towards 
oxidoreductases, this being the authors’ particular interest, with 119 cysteines out of the 
total 322 cysteines being from oxidoreductases [78]. There are obvious drawbacks to 
using such an algorithm, most importantly that does not take into account the dynamic 
nature of protein architecture. Since the oxidation susceptibility of reversibly oxidised 
protein thiols has been found to be largely based on solvent accessibility, protein 
conformation would be an important determinant in cysteine oxidation [78]. Also, 
success of the algorithm at predicting oxidation susceptibility is dependent on the types 
of oxidation, as well as the types of proteins, that are present in the database used. In this 
case, it was found that COPA was generally unsuccessful at predicting oxidation 
suscuptibility of thiols that form intermolecular disulfides due to the fact that there are 
only 5 examples of these in the database and because this type of oxidation is generally 
found to involve large changes in protein conformation [78]. However, at the time of 
writing, COPA is the only algorithm developed that predicts oxidation susceptibility of 
reversibly oxidised protein thiols, and with a success rate of around 80% it gives a 
reasonable starting point for experimentation. 
The cysteines predicted to be susceptible to oxidation by the COPP web interface were 
Cys31, Cys423 and Cys424 (Table 3.1). Cys358 was not predicted by this program to be 
susceptible to oxidation but it was included in the study due to the experimental findings 
by Cantley’s group (Table 3.1)[34]. The cysteines were mutated to alanine to remove the 
cysteine group and serine to mimic a cysteine residue that cannot be oxidised (Table 3.1). 
Cys424 was also mutated to Leu, the equivalent residue in M1PYK due to the finding 
that this mutation in rat M2PYK leads to loss of allosteric regulation and maintainance of 




Table 3.1 M2PYK point mutations made and reasons for choosing these cysteines  
M2PYK mutant Reason for making mutant 
C31A 
Identified by COPP web interface as being susceptible to oxidation. 
Mutating to alanine removes the reactive cysteine group.  
C423S 
Identified by COPP web interface as being susceptible to oxidation. 
Mutation to serine is to mimic a reduced cysteine that cannot be oxidised. 
C424A   Decreased allosteric effect [79] 
C424S Mutation to serine to mimic a reduced cysteine that cannot be oxidised 
C424L 
Loss of allosteric regulation, and protein in active R-state in absence of 
activators [79] 
C358A Identified by Cantley’s group as the key cysteine residue regulating M2 
PYK activity [34]  C358S 
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10 20 30 40 50 60 70
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMN
80 90 100 110 120 130 140
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
VARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATL
150 160 170 180 190 200 210
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
KITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVN
220 230 240 250 260 270 280
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
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290 300 310 320 330 340 350
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
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360 370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEAS
430 440 450 460 470 480 490
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
FKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRV













Figure 3.2 Positions of cysteines in M2PYK sequence and structure 
Top, cartoon of M2PYK monomer showing positions of cysteines in folded structure. 




Figure 3.3 Cysteine 31 is located on the A-A interface.  
It is identified in COPP web interface as being susceptible to oxidation. 
 
 
Figure 3.4 Cysteines 423 and 424 are located in the alternatively spliced region of 
M2 PYK on the C-C interface.  
Cys424 is specific to M2 PYK, the equivalent residue in M1 PYK being a leucine. It has 
been found that mutating this residue in rat M2 PYK to the M1 equivalent residue 
resulted in loss of allosteric regulation [79]. Both cysteines are identified by the COPP 







Figure 3.5 Cysteine 358 is located in a β barrel that includes essential catalytic 
residues.  
β barrel is shown in red and C358 is located at the bottom of one of the β strands. It is 
this cysteine that Cantley’s group claims is the cysteine primarily responsible for 
inhibition of M2PYK by oxidation [34]. The COPP web interface predicts that this 
cysteine is not susceptible to oxidation. The algorithm used by COPP (COPA) utilises 
structural data to predict the susceptibility of cysteine thiols to reversible oxidation with 




3.2. Results and Discussion 
 
3.2.1 Aims 
The aims of this part of the project were to produce, purify and biochemically 
characterise seven cysteine point mutants of human M2PYK in order to investigate which 
cysteine(s) are involved in the regulation of M2PYK by oxidation. 
 
3.2.2 Expression and purification of M2PYK and mutants 
His6M1PYK, His6M2PYK, and His6M2PYK mutants were overexpressed in BL21 E. 
coli cells (Novagen). All proteins expressed under the same conditions (Figure 3.4). Cell 
pellets were lysed and the soluble fraction passed over a 5ml IMAC Hitrap HP sepharose 
column (GE Healthcare), precharged with cobalt at 2ml/min. Eluted M PYK was pooled 
and loaded onto a superdex 200 26/60 XK gel filtration column pre-equilibrated with 
PBS-CM (Sigma). Fractions containing M PYK were pooled and concentrated a vivaspin 
column with molecular weight cut-off of 30 kDa. Chromatograms and SDS-PAGE gels 


























































































































































































































































































Figure 3.6 M2PYK cysteine mutant expression gels 
SDS-PAGE of whole cell extracts pre- and post-induction of M PYK cultures with 1mM 
IPTG in 2xTY media at 18ºC overnight. Results show that all cysteine mutants express 
well under these conditions, the same as wild-type (Compare lanes Post-C31A, Post-
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Figure 3.7 Purification of M2PYK C31A.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-5. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column. Inset, SDS-PAGE gel of indicated fractions 1-3 
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Figure 3.8 Purification of M2PYK C358A.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-5. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-equilibrated in PBS-CM. Inset, SDS-PAGE gel 
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Figure 3.9 Purification of M2PYK C358S.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-5. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-equilibrated in PBS-CM. Inset, SDS-PAGE gel 
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Figure 3.10 Purification of M2PYK C423S.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-5. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-equilibrated in PBS-CM. Inset, SDS-PAGE gel 
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Figure 3.11 Purification of M2PYK C424A.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-6. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-equilibrated in PBS-CM. Inset, SDS-PAGE gel 
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Figure 3.12 Purification of M2PYK C424S.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-6. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-quilibrated in PBS-CM. Inset, SDS-PAGE gel of 
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Figure 3.13 Purification of M2PYK C424L.  
Top panel, IMAC elution profile from a 5ml IMAC hitrap HP column. Inset, SDS-PAGE 
gel of indicated fractions 1-7. Bottom panel, gel filtration elution profile from a superdex 
200 26/60 XK gel filtration column pre-equilibrated in PBS-CM. Inset, SDS-PAGE gel 
of indicated fraction 1 showing that protein was obtained to a high level of purity. 
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All M2PYK cysteine mutants were purified to high level of purity and with good yields. 
The difference in gel filtration elution profiles suggest that mutation of these cysteines 
has an effect on tetramer:dimer:monomer equilibrium of M2PYK, although it would be 
necessary to carry out analytical gel filtration to confirm this (Figures 3.7-3.11, bottom 
panel). 
 
3.2.3 DLS of M2PYK cysteine mutants 
DLS was carried out on all M2PYK cysteine mutants after storage at -80ºC. The results 
are shown in Figure 3.12. The “size distribution by volume” graphs show a single peak of 
particles at close to the expected size of about 240kDa for a M2PYK tetramer. The 
molecular weights are estimated by the DLS software and are based on empirical mass 
vs. size calibration curve. The difference between the estimated molecular weights and 
the actual size of a M2PYK tetramer is probably due to the equilibrium between tetramer, 
dimer and monomer. The estimated molecular weight would therefore be an average of 
the different oligomeric states present. The mutants with smaller estimated molecular 
weights may have a higher proportion of monomer and dimer than those with higher 







Figure 3.14 Dynamic light
Scattering (DLS) analysis of
M2PYK cysteine mutants shows
that all are stable after storing at
-80ºC in PBS-CM.
The molecular weights are
estimated by the DLS software
and are based on empirical mass
vs. size calibration curve. Actual 


















3.2.4 M2PYK cysteine point mutations effect on enzyme activity 
The activity of M2PYK WT, M1PYK WT and M2PYK cysteine mutants were analysed 
using the LDH-coupled assay in the presence of 1mM PEP and 1mM DTT. Consistent 
with previously published results using rat M2PYK, the human M2PYK C424L mutant 
had similar activity to M1PYK WT [79]. Most of the cysteine mutations result in 
decreased activity compared to M2PYK WT, with M2PYK C358A showing the most 
significant reduction (Figure 3.15). This finding is in agreement with published results 











































































Figure 3.15 M2PYK C358A shows most significant reduction in activity compared 
to M2PYK WT. Activity was measured using the LDH-coupled assay in the presence of 
1mM PEP and 1mM DTT, without F-1,6-BP. Velocity values (in Abs units/sec) were 
calculated and are presented here as a percentage of the M2PYK WT velocity. Results 
show that most mutants result in decreased activity compared to M2PYK WT, with the 
exception of M2PYK C424A and M2PYK C424L. M2PYK C358A mutation results in 
the most significant reduction in activity compared to M2PYK WT.
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3.2.5 Cysteine point mutants do not protect M2PYK from oxidative damage 
Activity assays in the presence of 1mM DTT or 10µM H2O2 were carried out using the 
Kinase Glo reagent (Promega) in order to investigate whether any single cysteine is 
important for regulation of M2PYK by regulation. If one cysteine was of particular 
importance then it would be expected that mutating it to a residue resistant to oxidative 
damage would result in maintenance of M2PYK activity in presence of H2O2. However, 
the results of this experiment show that none of the cysteine point mutations protect 
M2PYK from oxidative damage (Figure 3.16). As a control, M1PYK WT activity is 
unaffected by treatment with 10µM H2O2.  
 
 
Figure 3.16 M2PYK cysteine point mutants do not prevent oxidation of M2PYK.  
M1PYK is unaffected by treatment with 10µM H2O2, whereas the activities of M2PYK 
and all cysteine mutants are dramatically decreased by H2O2. Error bars are based on 





3.2.6 Kinetics of M2PYK mutants 
Kinetics data for three of the M2PYK cysteine mutants as well as M2PYK WT was 
measured using the LDH-coupled assay varying the concentration of the substrate PEP. 
The mutants chosen were M2PYK C358A, M2PYK C358S, and M2PYK C424A. 
M2PYK C358A and M2PYK C358S were chosen for further study due to the apparent 
importance of this cysteine in the regulation of M2PYK as shown by Anastasiou et al. 
[34]. M2PYK C424A was chosen for further study because this cysteine is the only 
cysteine that is present in M2PYK but not M1PYK. The results are shown in Table 3.2 
and Figure 3.17. The Km values for M2PYK WT of 0.9mM PEP without F-1,6-BP and 
0.14mM PEP with F-1,6-BP are similar to previously obtained values (Table 1.1). Vmax 
values vary significantly between studies from as little as 12 U/mg (Table 1.1; Jakub 
Nowak MSc report) to as much as 724 U/mg (Table 1.1; [48]). This could be due to 
differences in the way the kinetics assays were carried out as the longer M2PYK is left at 
the low concentrations used for these assays, the more it dissociates into the less active 
dimeric and inactive monomeric states. In these experiments, as well as those carried out 
by Jakub Nowak, M2PYK protein was left at low concentrations at room temperature for 
2-3 hours before measuring activity in order to allow the tetramer:dimer:monomer ratio 
to reach equilibrium. The details of the protocol used for the published paper, in which a 
Vmax of 724 U/mg was obtained, are not described but perhaps they used a higher 
concentration of M2PYK and/or did not leave the protein to reach oligomeric equilibrium 
at low concentrations before measuring the activity leading to a higher proportion of 








Table 3.2 Summary of kinetics data collected for M2PYK cysteine point mutants. 
 
All three mutants studied showed a significant decrease in Vmax compared to M2PYK 
WT and small differences in Km (Table 3.3 and Figure 3.16). M2PYK C358A has the 
highest Km value which is in agreement with the activity results shown in Figure 3.15 in 
which M2PYK C358A was found to have the lowest activity measured in the presence of 
1mM PEP. Based on the results from the thermal denaturation assay, which show that 
M2PYK C358S thermal stability is unaffected by the presence of F-1,6-BP (Table 3.3), it 
was expected that F-1,6-BP would not activate this mutant. However, all three mutants 
were found to be allosterically activated by F-1,6-BP (Table 3.2 and Figure 3.17). The 
reason for this could be based on the fact that the C358S mutation appears to stabilise the 
tetrameric form of M2PYK (Figure 4.7). The increase in melting temperature on addition 
of F-1,6-BP to M2PYK WT could be due to the fact that F-1,6-BP causes M2PYK to 
form more stable tetramers. Since M2PYK C358S is already mostly tetrameric, addition 
of F-1,6-BP would not be expected to make much difference to the stability of the 
protein. Perhaps M2PYK C358S is a tetramer, similar in conformation to M2PYK with 
phenylalanine, and binding of F-1,6-BP changes the conformation of the mutant to the 
active R-state [22]. This is a conceivable hypothesis given that C358 is situated close to 
the phenylalanine binding pocket and the pivot point of the rigid body rotation that occurs 
in the transition of inactive T-state to active R-state [22]. 
Protein Activity 
Kinetics (no F-1,6-BP)* Kinetics (+ F-1,6-BP)* 
Vmax (U/mg) Km [PEP mM] Vmax (U/mg) Km [PEP mM] 
M2PYK WT Active 97 0.9 110 0.17 
M2PYK C358A Active 34 1.5 68 0.14 
M2PYK C358S Active 34 0.9 68 0.13 
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Figure 3.17 Kinetics of M2PYK cysteine mutants show that the mutants have 
decreased activity compared to M2PYK WT. Kinetics data for M2PYK WT and 
M1PYK WT (Top left), M2PYK C424A (Top right), M2PYK C358S (Bottom left), and 
M2PYK C358A (bottom right). PYK activity was measured using the LDH-coupled 
assay at room temperature. PYK samples were incubated at 0.0025 mg/ml for 3 hours at 
room temperature before measuring activity in order to ensure oligomeric equilibrium 
was reached. FBP = Fructose-1,6-bisphosphate. 
66 
 
3.2.7 How do the cysteine point mutations affect thermal stability of M2PYK? 
Thermal denaturation assay results show that all mutations except C424A and C424L 
destabilise M2PYK (Figure 3.18 and Table 3.3). M2PYK C424A has the same melting 
temperature as M2PYK WT without additives and M2PYK C424L has a melting 
temperature 3ºC higher than M2PYK WT without additives (Figure 3.21).  
As expected, the allosteric activator F-1,6-BP has no effect on M1PYK thermal stability 
whereas it shifts the melting temperature of M2PYK WT by +5ºC (Table 3.3). All 
M2PYK cysteine mutants except M2PYK C358S have a shift in melting temperature in 
response to F-1,6-BP similar to M2PYK WT. This is an interesting and unexpected 
observation given the distance of C358S from the F-1,6-BP binding site, however it is 
supportive of the theory that C358 is an important cysteine in the regulation of M2PYK 
by oxidation. 
In the presence of 1mM H2O2 the melting temperature of M2PYK WT is decreased by 
5ºC indicating that the structure of the enzyme is destabilised by oxidation, whereas it has 
no effect on the melting temperature of M1PYK (Table 3.3). The mutant M2PYK C423S 
is the only one for which oxidation has little effect on its melting temperature (Table 3.3). 
Interestingly, this mutant also has two melting peaks in the presence of DTT and is the 
only protein investigated which is significantly stabilised by DTT (+9ºC) (Figure 3.18 
and Table 3.3). These results indicate that C423 could also be involved in the regulation 
of M2PYK by oxidation. 
The effect of H2O2 and DTT on the melting temperatures of the M PYK proteins in the 
presence of F-1,6-BP was also measured to find out if stabilisation of the protein by the 
allosteric activator could protect it from oxidative damage (Table 3.3). This is of interest 
given the hypothesis put forward by Cantley’s group that M2PYK is protected from 
oxidation when in the active R state [34]. The results show that M2PYK is destabilised 
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by H2O2 even in the presence of F-1,6-BP which could suggest that M2PYK is not 
protected from oxidation when in the R-state (Table 3.3). However, another explanation 
could be that the addition of H2O2 at the same time as F-1,6-BP allowed the H2O2 to have 
an effect before the conformational change was induced by F-1,6-BP. 
 
 
 Table 3.3 Summary of thermal denaturation data. * = Broad peak in -dRFU/dT plot,     
** = Protein denatured at start of data collection. Two values in the same cell indicates a 
two phase melting event shown by two peaks in the –d(RFU)/dT plot.       
 
Protein Melting temperature (˚C) with: 
No additive 1mM H2O2 1mM DTT 1mM FBP 1mM FBP + 
1mM H2O2 
1mM FBP + 
1mM DTT 
M2PYK 49 44 49-50 54 49 55 
M1PYK 50/63 50/63 50/63 - - - 
M2PYK C31A 44 41* 46 52 44* 53 
M2PYK C358A 45 38/44 47 52 48* 53 
M2PYK C358S 45 ** 46 45 40* 47 
M2PYK C423S 46 46* 46/55 54 49* 55 
M2PYK C424S 46 ** 47 51 ** 52 
M2PYK C424A 49 46 49/53 55 50* 55 
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Figure 3.18 Thermal stability of M2PYK cysteine mutants 
Thermal denaturation data for M PYKs and mutants in the presence of 1mM DTT 
(green), 1mM H2O2 (blue), 1mM F-1,6-BP (black), or with no additives (red). Row 1, 
M1PYK and M2PYK WT. Row 2, M2PYK C31A and M2PYK C358A. RowM2PYK 
C31A and M2PYK C358A. Row 3, M2PYK C358S and M2PYK C423S. Row 4, C424S 
and M2PYK C424A. Row 5, M2PYK C424L. RFU = relative fluorescence units, 




In conclusion, seven M2PYK cysteine mutants were successfully expressed in E.coli and 
purified to a high level of purity and with good yields (Figures 3.6-3.13). Differences in 
gel filtration profiles indicate that modification of these cysteines could have an effect on 
the tetramer:dimer:monomer equilibrium of M2PYK (Figures 3.7-3.13). Furthermore,  
DLS results show that all M2PYK cysteine mutants store well at -80˚C in PBS-CM. 
Enzyme activity assay results show that M2PYK C424L has high activity comparable to 
M1PYK even in the absence of F-1,6-BP. This is consistent with published results using 
rat M2PYK in which the same mutation resulted in loss of allostery and activity similar 
to M1PYK [79]. M2PYK C424A has activity very similar to M2PYK WT, whereas all 
other cysteine mutants studied showed decreased activity compared to wild-type, with the 
most pronounced reduction seen for M2PYK C358A (Figure 3.15). It was also shown 
that no single cysteine mutation could protect M2PYK from decrease in enzyme activity 
caused by H2O2, whereas M1PYK activity was mostly unaffected by the same treatment 
(Figure 3.16). 
As expected, the thermal stability of M1PYK was unaffected by addition of F-1,6-BP 
whereas the melting temperature of M2PYK was increased by 5˚C by the allosteric 
activator (Table 3.3). Additionally it was found that all M2PYK cysteine mutants show a 
shift in melting temperature in response to F-1,6-BP similar to M2PYK WT, with the 
exception of M2PYK C358S (Table 3.3). It is unclear why this should be the case 
because F-1,6-BP clearly has an affect on the activity of C358S (Table 3.2 and Figure 
3.17). However, the different behaviour of this mutant in the presence of F-1,6-BP 
despite its distance from the F-1,6-BP binding site could be supportive of the theory that 
C358 is an important cysteine in the regulation of M2PYK by oxidation.  
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The addition of 1mM H2O2 has no affect on the thermal stability of M1PYK whereas it 
decreased the melting temperature of M2PYK WT by 5˚C indicating that oxidation has a 
destabilising effect on the structure of M2PYK but no effect on M1PYK (Table 3.3 and 
Figure 3.18). This agrees with the enzyme activity results which show that M1PYK 
activity is unaffected by H2O2. The thermal denaturation results also show that oxidation 
by H2O2 has little affect on M2PYK C423S (Table 3.3). This mutant is also the only 
protein in this study that is significantly stabilised by addition of DTT (Table 3.3). These 
results suggest that M2PYK C423 could be an important cysteine in the regulation of 
M2PYK by oxidation.    
It is interesting to speculate that oxidation and effector binding compete so that M2PYK 
would be protected from oxidation when in the active R-state. Although the results shown 
in Table 3.3 (1mM FBP + 1mM H2O2) do not appear to support this hypothesis, this may 
be due to the simultaneous addition of F-1,6-BP and H2O2 to the protein.  It seems likely 
that F-1,6-BP binding would prevent oxidation because it is known that addition of F-1,6-
BP induces tetramerisation [22]. Since the majority of M2PYK cysteines likely to be 
involved in M2PYK oxidation are located at the tetramerisation interfaces it is logical to 
conclude that these cysteines would be protected from oxidation in the M2PYK tetramer. 
In support of this hypothesis, another protein Galectin-1 has been found to have reduced 
sensitivity to oxidative inactivation after binding of its ligand lactose, which enhances 
dimer formation [80]. In order to accurately test the hypothesis that M2PYK binding to 
F-1,6-BP prevents oxidation it would be necessary to repeat the thermal denaturation 
assays incubating M2PYK in the presence of F-1,6-BP to allow transition to the active R-




Chapter 4: The role of nitric oxide in M2PYK regulation (- In 





4.1.1 Nitric oxide as a signalling molecule 
Nitric oxide (NO) was thought only to be an atmospheric pollutant until, in 1987 and the 
years that followed, it was found to be synthesised in vivo and to have extremely similar 
biochemical properties to the previously described endothelium-derived relaxation factor 
(EDRF) [81]. NO is a by-product of the metabolism of L-arginine to L-citrulline 
catalysed by the enzyme  nitric oxide synthase (NOS) (Figure 4.1)[82]. There are three 
known isoforms of NOS; NOS1, NOS2 (iNOS) and NOS3. NOS1 and NOS3 are also 
known as nNOS and eNOS, due to the fact that they were initially cloned in neural and 
endothelial cells respectively, and are dependent on Ca
2+
-calmodulin [83]. NOS2, also 
known as iNOS, was first identified in macrophages and its binding to calmodulin is 
independent of calcium allowing it to consistently produce high levels of NO for long 
periods [84]. Many cell types have been found to express one or more of these isoforms 
[85].  NO typically acts via two types of pathway, cyclic guanosine monophosphate 
(cGMP)-dependent or cGMP-independent [86]. In the cGMP-dependent pathway, NO 
interacts with the soluble guanylyl cyclase as well as cGMP-dependent protein kinase G, 




L-arginine NG-hydroxy-L-arginine Citrulline Nitric oxide
O2 O2
 
Figure 4.1 Reaction catalysed by Nitric oxide synthase (NOS).  





One of the ways that NO can function independently of cGMP is by post-translational 
modification of proteins by the coupling of a nitroso moiety to a reactive thiol group on a 
cysteine, a process known as S-nitrosylation [88]. It is thought that dinitrogen trioxide 
(N2O3) is the likely S-nitrosating species as NO itself is known to be a poor nitrosating 
agent [89]. N2O3 is produced from the reaction of NO with O2 (Eq. (1)(2)(3)). 
 
                                                ·NO  +  O2                    ONOO·             (1) 
                                              ONOO·   +   ·NO                 2·NO2            (2) 
                                                ·NO2  +  ·NO                      N2O3           (3) 
 
The reaction mechanism for S-nitrosylation of glutathione by N2O3 is shown in Figure 
4.2. In the first step, the thiol hydrogen is transferred to the N2O3 forming the reactive 







Figure 4.2 Possible chemical mechanism for the S-nitrosylation of glutathione by 
dinitrogen trioxide (N2O3).  
In the first step, the thiol hydrogen is transferred to the N2O3 forming the reactive thiyl 




Transfer of the nitroso moiety between proteins can also occur via nucleophilic attack on 
the nitrogen atom of the SNO, a process known as tranS-nitrosylation [89][90].  
It is believed that S-nitrosylation of proteins could be involved in regulation and 
signalling in a similar way to phosphorylation because, although there are multiple 
cysteine residues in a protein accessible for S-nitrosylation, only a few are specifically 
modified. There are a few different theories put forward as to how this specificity is 
achieved. Firstly, specific motifs around cysteine residues may allow for selective 
nitrosylation by creating the right chemical environment for the reaction to take place 
[91][92]. Secondly, subcellular co-localisation of S-nitrosylated proteins with NOS 
isoforms may allow for specificity by bringing target proteins into proximity with the 
relevant NOS isoform [93][94][95][96]. Finally, several “protein nitrosylases” have been 
described that directly transfer nitroso groups to target proteins via tranS-nitrosylation 
[97][98][99]. 
 
4.1.2 Nitric oxide and carcinogenesis 
Carcinogenesis often involves the elevated expression, overproduction, or abnormal 
activation of various mediators of inflammation, which include iNOS and NO [100]. 
Furthermore, the expression of iNOS has been found to be upregulated in many tumour 
types including lung [101][102], colon [103][104], melanoma [105], and breast cancers 
[106]–[108]. There are many laboratory and population-based studies that suggest a link 
between inflammatory damage and carcinogenesis [109]. For example, gastric 
inflammation, chronic hepatitis, cholecystisis, inflammatory atrophy of the prostate, and 
chronic pancreatitis are linked to cancers of the stomach, liver, gallbladder, prostate and 
pancreas, respectively [109].   
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The normal production of ROS/RNS during cellular metabolism is important for a variety 
of cellular functions, however oxidative stress can occur when a defect in the body’s 
ROS/RNS detoxification pathways is coupled with excessive production of ROS/RNS as 
a consequence of environmental stress, infection, or a metabolic disorder [110]. NO, and 
its derivative peroxynitrite, promotes inflammation-associated carcinogenesis through 
various mechanisms. These include the reaction of peroxynitrite with DNA to form 8-
nitroguanine, a biomarker of inflammation-associated cancers [111]–[113], suppression 
of DNA repair enzymes, and altered expression and covalent modification of numerous 
proteins leading to abnormal growth and proliferation of cells [86], [110].  
 
4.1.3 Nitric oxide and tumour progression 
NO derived from tumour cells has been reported to both promote and inhibit tumour 
progression [114][115]. The effect of NO on tumour progression is thought to be 
dependent upon the duration of NO exposure, cellular sensitivity to NO, and the type, 
activity and localisation of NOS isoforms expressed [116]. There are four explanations 
proposed for how NOS expression in tumour cells promotes tumour progression [116]. 
Firstly, migration and invasion of breast cancer and colon cancer cells have been found to 
be enhanced by iNOS and eNOS by acting through soluble guanylate cyclase (sGC) and 
the mitogen-activated protein kinase (MAPK) pathway [117]–[119]. Secondly, a 
correlation between iNOS expression and increased cell proliferation has been found in 
T-lymphoma cells [120]. Thirdly, NO may induce immune cell dysfunction thus allowing 
tumour cells to escape from immunosurveillance [121]. Finally, induction of iNOS in 
tumour cells has been found to increase expression of VEGF, which promotes 




Although induction of iNOS in tumour cells has been found to promote angiogenesis, 
there a few studies reporting that iNOS expression does not correlate with tumour 
progression [107][126]. Other studies have shown that there is no correlation between 
iNOS expression and VEGF expression in some human tissues [124]. This conflict may 
arise from the differences in tumour type, host tissues or tumour models. Also, in most of 
the studies the distribution and concentration of NO was not determined [116]. It has 
been reported that the response of tumour cells to iNOS induction is dependent on the 
status of p53, with one study showing that in p53 mutant cells induction of iNOS 
expression resulted in increased expression of VEGF, angiogenesis and tumour growth, 




















Tumour cells expressing wild-type p53 Tumour cells expressing non-functional mutant p53
 
Figure 4.3 Diagram summarising the relationship between p53 and NO signalling in 
cancer.  
Hypoxia induces NOS expression which leads to endogenous production of NO. High 
concentrations of NO lead to DNA damage, which results in apoptosis and necrosis, and 
p53 expression, which inhibits expression of the angiogenic factor VEGF thereby 
inhibiting metastasis. In tumour cells which express mutated non-functional p53, 
expression of VEGF is not inhibited and increases in response to endogenously produced 





4.1.3 S-nitrosylation of M2PYK 
In 2001, Jaffrey and Snyder published a paper describing the biotin-switch technique for 
isolating S-nitrosylated proteins [72]. This opened up the opportunity to map out the S-
nitrosylated proteome. In 2005, the S-nitrosylated proteome of murine macrophages was 
published which combined the biotin-switch technique with MALDI-TOF mass 
spectrometry (MS) to sequence and identify the isolated proteins [127]. It was in this 
study that M1/M2PYK was first identified as being S-nitrosylated. More recent studies 
have combined liquid chromatography with MS/MS to get more detail about peptides 
within the S-nitrosylated proteins that are S-nitrosylated and using this technique four 
M2PYK cysteines have been identified as being S-nitrosylated (Table 4.1 and Figure 
4.4).  
 
Table 4.1 Summary of M2PYK cysteines previously reported as being S-nitrosylated 
M2PYK cysteine 
nitrosylated 
Type of tissue Reference 
C49 
Murine macrophages 





Different mouse tissues 
[130] 
[129] 







































Figure 4.4 Positions of cysteines found to be nitrosylated in M1/M2PYK.  
Only one of the cysteines, C424, is present in M2PYK but not M1PYK. Top; cartoon 
representation of M1PYK and M2PYK tetramers with the positions of those cysteines 
that can be S-nitrosylated shown as red circles. Bottom; sequence alignment of human 
M1PYK and human M2PYK with positions of those cysteines that previously reported to 
be S-nitrosylated indicated by the red circles. 
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Another glycolytic enzyme that has been reported to be S-nitrosylated is glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) [131]. GAPDH S-nitrosylation at its active site, 
Cys145, promotes interaction of GAPDH with the E3 ubiquitin ligase Siah1 and results in 
nuclear translocation of the SNO-GAPDH-Siah1 complex leading to mechanisms that 
promote cell death [131]. Interestingly, M2PYK has been found to interact with the 
SUMO-E3 ligase PIAS3 which induces the sumoylation and subsequent nuclear 
translocation of M2PYK [132]. Nuclear M2PYK has been implicated in the enhancement 
of cell proliferation through various different mechanisms, for example phosphorylation 
of the ε-amino group of L-lysine of histone H1 by M2PYK leads to destabilisation of the 
nucleosome and chromatin thus allowing for DNA replication and cell proliferation 
[133], M2PYK interacts with and positively regulates the activity of the transcription 
factor Oct4 which is important in maintaining the pluripotent state of embryonic stem 
cells [134], and M2PYK has been found to translocate to the nucleus in response to 
interleukin-3 (IL-3) stimulation and to enhance cell proliferation in the absence of IL-3 
[135]. It is interesting to speculate that S-nitrosylation could promote nuclear 
translocation in a similar manner to GAPDH thus allowing for increased proliferation of 
tumour cells.  
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 4.2. Results and Discussion 
 
4.2.1 Aims 
The aims of this part of the project were to investigate whether human M2PYK is 
regulated by cysteine S-nitrosylation and, if so, to identify which cysteine(s) are 
modified. 
 
4.2.2 Human M2PYK is S-nitrosylated in vitro 
The biotin-switch assay was carried out on M1PYK WT, M2PYK WT, and three of the 
M2PYK mutants described in chapter 3 – M2PYK C423S, C424S and C358S (Figure 
4.4). A workflow of the biotin-switch assay is shown in Figure 4.5A. Protein samples 
were treated with the nitrosylating agent CysNO followed by blocking of the free 
cysteines with methylmethanethiosulfonate (MMTS). NO groups were then removed and 
the resulting free cysteines labelled with biotin-HPDP before running samples on SDS-
PAGE gel and carrying out a western blot with anti-biotin antibody to identify 
biotinylated proteins (Figure 4.5A). The results show that both M1PYK and M2PYK are 
nitrosylated, but M1PYK is nitrosylated to a lesser extent than M2PYK (Figure 4.5B). 
Mutation of Cys358 to serine results in almost complete loss of the biotin signal (Figure 
4.5B). A naïve analysis would suggest that this cysteine is the main target of S-
nitrosylation, however this does not take into consideration the possibility that the 
mutation could lead to change in conformation and/or oligomeric state that could result in 






4.2.3 Mass spectrometry identifies biotinylated peptide containing Cys326 
Analysis of the protein samples in the SDS-PAGE gels of WT M2PYK by mass 
spectrometry did not detect any peptide containing biotin labelled Cys358. However, a 
peptide containing Cys326 was found to be biotinylated in both M1PYK and M2PYK 
(Figure 4.5C). This is an interesting finding because it has been reported that M2PYK 
Cys326 is stably nitrosylated in a study in which it was discovered that there are a subset 
of proteins that are not subject to de-nitrosylation by cytosolic reducing agents [130]. In 





Figure 4.5 In vitro biotin-switch assay shows that M2PYK can be nitrosylated and 
that mutation of cysteine 358 to serine prevents this nitrosylation from occurring.  
A. Diagram showing workflow of biotin-switch assay. B. SDS-PAGE and western blot of 
M1- and M2PYK and mutants that have undergone the biotin-switch assay. Molecular 
weight markers are ColorPlus Prestained protein ladder. (Carried out by Dr. Manda Yu) 
C. Bar chart showing normalised abundance of the peptide containing biotin-labelled 
Cys326 from mass spectrometry analysis of SDS-PAGE bands (Carried out by Dr. 
Thierry LeBihan) M1- = M1PYK without CysNO treatment, M1+ = M1PYK with 




4.2.4 Tetramerisation of M2PYK C358S could mask C326 from nitrosylation 
Cys326 is located at the large A-A interface of M2PYK with only Arg294 masking it 
from the solvent when M2PYK is monomeric (Figure 4.6). Due to this location, Cys326 
would be completely masked from the solvent when M2PYK is tetrameric and therefore 
would not be available for nitrosylation. A possible explanation for the lack of 
nitrosylation of M2PYK C358S is that this mutation causes M2PYK to be much more 
tetrameric thus shielding Cys326 from nitrosylation. The proximity of Cys358 to the 
phenylalanine binding pocket means that this hypothesis is feasible [22]. Phenylalanine is 
an allosteric inhibitor of M2PYK and acts by holding M2PYK as an inactive tetramer 
[22]. In order to test this hypothesis, analytical gel filtration was carried out on M2PYK 
C358S in order to find out its oligomeric equilibrium compared to M2PYK WT. The 
results were striking and show that M2PYK C358S has a much higher proportion of 














Figure 4.6 Cys326 is located on the A-A interface with only Arg294 between it and 
the solvent when M2PYK is monomeric.  
A. M2PYK tetramer showing that Cys326 (red spheres) is buried. B. M2PYK monomer 
rotated 90º to show that when M2PYK is monomeric Cys326 is exposed to the solvent. 
C. Zoom in of boxed region in B showing that Arg294 is the only residue between 
Cys326 and the solvent. In this structure (PDB ID: 3SRD), Arg294 appears to be held in 






Figure 4.7 M2PYK C358S has a higher proportion of tetramer compared to 
M2PYK WT.  
Analytical gel filtration was carried out using a superdex 200 PC 3.2/30 with a protein 
concentration of 0.1mg/ml. Protein samples were incubated at 0.1 mg/ml overnight at 
room temperature in order to allow oligomeric equilibrium to be reached. Absorbance 
was measured at 214nm. 
 
4.2.5 Expression of M2PYK C326S 
In order to test the hypothesis that Cys326 is the cysteine residue that is nitrosylated in 
human M2PYK in vitro, the point mutation M2PYK C326S was made using the 
QuikChange Lightening site-directed mutagenesis kit (Agilent technologies). This mutant 
did not express at all under the same conditions as the wild type and other mutants so 
expression trials were carried out. Mutated plasmid was transformed into three different 
cell lines; BL21*, C41(DE3), and C43(DE3). Expression was induced with 1mM IPTG at 
20ºC, 30ºC, and 37ºC and expression was tested by SDS-PAGE after induction for 3 
hours and overnight in LB media and 2xTY media (Figure 4.8). Expression was also 
tested in Enpresso media (BioSilta) (Figure 4.8). The conditions chosen for expression of 
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His6M2PYK C326S were inducing at 30ºC for 3 hours using BL21* cell line in LB 
media (Figure 4.8, top right). 
 
4.2.6 Purification of M2PYK C326S 
Purification of M2PYK C326S was carried out by Meng Yuan essentially as described in 
sections 2.1.3 and 2.1.4 with a few changes due to the instability of this mutant. Cell 
pellets containing overexpressed His6M2PYK C326S were lysed and the soluble fraction 
was passed over a 5ml IMAC Hitrap FF sepharose column (GE Healthcare) precharged 
with cobalt at a constant flow rate of 2ml/min (Figure 4.9, top). Eluted M2PYK C326S 
protein was pooled and concentrated using a vivaspin column with molecular weight cut-
off of 30 kDa. The concentrated protein was then loaded onto a Hiload superdex 200 
16/60 column pre-equilibrated in PBS-CM with 10% glycerol (Figure 4.9, bottom). 
Eluted protein was pooled and concentration using a vivaspin column with molecular 
weight cut-off of 30 kDa. The concentration of the concentrated protein was measured as 
described in section 2.1.5 using a nanodrop spectrophotometer. The final concentration 
































































































































Figure 4.8 M2PYK C326S expression trials.  
M2PYK C326S pET28a was transformed into three different cell lines; C41(DE3), 
C43(DE3), and BL21*. Expression was tested in LB media and 2xTYmedia at 3 different 
temperatures and 2 incubation times. Enpresso media was also tested using the standard 
protocol. Labels: 1-molecular weight markers, 2-Pre-induction, 3-3h post induction at 
20ºC, 4-3h post induction at 30ºC, 5-3h post induction at 37ºC, 6-overnight post 
induction at 20ºC, 7-overnight post induction at 30ºC, 8-overnight post induction at 37ºC. 


































































Figure 4.9 Purification of M2PYK C326S.  
Top panel, IMAC elution profile from a 5ml Hitrap FF sepharose column pre-charged 
with cobalt. Inset, SDS-PAGE gel of indicated fractions. Lane 1 = pre-induction, lane 2 = 
sample loaded onto IMAC column, lane 3 = flow through. Bottom panel, gel filtration 
elution profile from a Hiload superdex 200 16/60 column pre-equilibrated in PBS-CM 




4.2.7 M2PYK C326S mutation prevents tetramerisation 
M2PYK C326S was found to form a cloudy precipitate very soon after purification when 
stored in PBS-CM and did not respond well to concentrating. Addition of 10% glycerol 
to the protein after purification was effective to prevent formation of the precipitate. 
Analytical gel filtration was used to compare the oligomeric state of the M2PYK C326S 
mutant with M2PYK WT. The protein samples were incubated overnight at a 
concentration of 0.1 mg/ml at room temperature before loading onto a superdex 200 PC 
3.2/30 column. As expected, M2PYK WT protein eluted in two prominent peaks 
corresponding to tetramer and monomer (Figure 4.10). However, M2PYK C326S protein 
eluted as a single peak corresponding to monomer (Figure 4.10). The apparent inability 
of the M2PYK C326S mutant to form tetramers highlights the importance of this cysteine 
in regulating the oligomeric state of M2PYK. It is therefore an interesting possibility that 
S-nitrosylation of C326 could result in the monomerisation of M2PYK thus allowing for 
interaction with protein partners and nuclear translocation of M2PYK in a similar manner 





















Figure 4.10 M2PYK C326S is monomeric.  
Analytical gel filtration of M2PYK WT and M2PYK C326S with a superdex 200 PC 
3.2/30 column after incubation at 0.1 mg/ml for 12 hours shows that M2PYK C326S is 
exclusively monomeric. 
 
4.2.8 Use of serine as a cysteine substitute 
Serine is commonly used as a substitute for non-disulphide bond forming cysteines due to 
the apparent similarity in the side-chains, the only difference being a change from an 
oxygen atom in serine to a sulphur atom in cysteine. However, the results from this study 
show that substitution of cysteine with serine can have a significant effect on the 
oligomeric state and stability of a protein. Substitution of Cys358 with serine resulted in a 
much higher proportion of tetramer compared to M2PYK WT at physiologically relevant 
concentration and changing Cys326 to serine resulted in exclusively monomeric protein 
(Figures 4.7 and 4.10). The effect of the M2PYK C358S mutation on oligomeric state is 
important to consider when interpreting the results published by Cantley’s group in which  
the M2PYK C358S mutant was used to demonstrate that oxidation of this cysteine in 
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M2PYK effects oligomeric state [34]. They used co-precipitation experiments to show 
that exposing M2PYK to oxidising conditions in the cell, induced by addition of diamide 
to cell growth media, resulted in no co-precipitation of Flag-M2PYK WT with 
endogenous M2PYK. However, Flag-M2PYK C358S co-precipitated with endogenous 
M2PYK even in the presence of oxidising conditions [34]. Given the results found here 
(Figure 4.7), it is possible that the formation of hetero-oligomers of M2PYK C358S with 
endogenous M2PYK WT could push the oligomeric equilibrium more towards tetramer. 
It is also probable that mutation of Cys358 to serine also changes the conformation of the 
protein given that, although M2PYK C358S is mostly tetrameric and would therefore be 
expected to have stability similar to M1PYK, thermal denaturation assay results show 
that M2PYK C358S is less thermally stable that M2PYK WT (Figure 3.21 and Table 
3.2). This adds another layer of complexity to interpretation of the experiments carried 
out by Cantley’s group using M2PYK C358S because the mutant is not equivalent to 




In conclusion, it is shown here for the first time that both human M2PYK and M1PYK 
are S-nitrosylated in vitro using the biotin-switch assay (Figure 4.5). M1PYK is S-
nitrosylated to a lesser extent than M2PYK (Figure 4.5). In addition, mutation of Cys358 
to serine results in almost complete loss of S-nitrosylation whereas the other cysteine 
mutants tested were largely unaffected (Figure 4.4). These results indicate that Cys358 
could be the main target of S-nitrosylation. However, analysis of the biotinylated protein 
samples failed to detect any peptide containing biotin-labelled Cys358. Instead a peptide 
containing biotinylated Cys326 was detected in both M1PYK and M2PYK (Figure 4.5C). 
This is in agreement with two published studies; one found M2PYK to be amongst a 
subset of stably nitrosylated proteins with Cys326 being the S-nitrosylated cysteine, the 
other identified mouse M2PYK to be nitrosylated on Cys326 [137][136].  
One possible explanation for the fact that Cys358 was not detected by mass spectrometry 
is that this cysteine is not the nitrosylated cysteine. Instead, the mutation of this cysteine 
to serine could cause a conformational change in the protein which results in Cys326 
being buried and inaccessible to nitrosylating agents. It has been shown here that M2PYK 
C358S is much more tetrameric than wild-type M2PYK at physiological concentrations 
(Figure 4.7). The tetrameric nature of this mutant would shield Cys326 from nitrosylation 
due to the location of this cysteine in the A-A interface of the M2PYK tetramer (Figure 
4.6). 
To test this hypothesis, the mutant M2PYK C326S was made, expressed and purified 
with the goal of carrying out the biotin-switch assay with it (Figures 4.8 and 4.9). This 
mutant was more difficult to express and was mostly found in the insoluble fraction. As a 
result the yields were relatively low. The protein product was found to be unstable and 
95 
 
required 10% glycerol to remain in solution. Analytical gel filtration shows that M2PYK 
C326S is completely monomeric at physiological concentrations indicating that 
modification of this cysteine could be important in regulating the oligomeric state of 
M2PYK and thus its activity (Figure 4.10). Furthermore it has been found that this 
mutant is inactive (data not shown).  
Before the M2PYK C326S mutant is used for further experimentation, the structural 
integrity of the protein should be tested. Although DNA sequencing of the plasmid used 
for expression of the mutant has been carried out and the correct DNA sequence 
confirmed, it may be advisable to analyse the purified protein by mass spectrometry to 
confirm that the correct mutation is present. The overall conformation and fold of the 
mutant could also be analysed using circular dichroism in order to confirm that the loss of 
activity is not due to incorrect protein folding. 
Serine is commonly used as a substitute for cysteines because it appears that their side-
chains are very similar, only differing in one atom. The results presented here show that 
substitution of cysteine with serine can result in dramatic changes in the conformation of 
a protein. Therefore, the commonly held assumption that proteins with cysteines mutated 
to serine are structurally equivalent to wild-type, other than there susceptibility to 
oxidation, needs to be treated with caution.    
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5.1.1 Human M1- and M2PYK structures  
There are 17 M2PYK structures and one M1PYK structure deposited in the PDB. The 
details of these structures are recorded in Table 5.1. The resolution of the structures 
ranges from 1.60 Å to 2.90 Å, with the majority being above 2.00 Å (Table 5.1). The 
most common space group seen is P 21 with unit cell dimensions of α=γ=90˚, β= 90-106˚, 
a= 80-170 Å, b= 70-156 Å, c= 91-170 Å (Table 5.1). 
Only two of the deposited M2PYK structures include point mutations and both of these 
are located in the F-1,6-BP binding pocket (Table 5.1, 4FXJ and 3G2G). 4FXJ is the 
structure of M2PYK R489A in complex with the allosteric inhibitor phenylalanine. This 
mutant was made in vitro to prevent F-1,6-BP contamination during expression and 
purification of the protein in order to allow crystallisation of the protein in the inactive 
conformation [22]. 3G2G is the structure of M2PYK S437Y, which is a naturally 
occurring M2PYK SNP resulting in reduced binding of the allosteric activator F-1,6-BP. 
 
5.1.2 M2PYK mutants discussed in this chapter 
The structures of two cysteine point mutants of M2PYK, C358S and C424A, are 
presented in this chapter. The locations of these cysteines in the structure of the M2PYK 
monomer is shown in figure 5.1. Diffracting crystals of M2PYK C358A were also 
obtained, although they did not diffract to a high enough resolution for further 
processing. It has been shown previously that mutation of the equivalent cysteine to more 
hydrophobic residues in rat M2PYK resulted in loss of allosteric regulation [79]. In 
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chapter 4 it was shown that mutation of C358 to Ser resulted in M2PYK becoming more 
tetrameric (Figure 4.7). The analysis of the structures of these mutants could give 






Figure 5.1 Positions of C358 and C424 in M2PYK monomer 
View of M2PYK monomer showing the positions of C358 and C424 (Green spheres)  
 
 
Table 5.1 Summary of human M1- and M2PYK structures deposited in the PDB. TLA= 
L-Tartaric acid  *M2PYK activators; DZG= 1-(2,3-dihydro-1,4-benzodioxin-6-
ylsulfonyl)- 4-[(4-methoxyphenyl)sulfonyl]piperazine, DYY= 1-[(2,6-
difluorophenyl)sulfonyl]-4-(2,3-dihydro- 1,4-benzodioxin-6-ylsulfonyl)piperazine, D8G= 
6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro- 5H-thieno[2',3':4,5]pyrrolo[2,3-
d]pyridazin- 5-one, 3SZ= 3-{[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)- 1,4-
diazepan-1 yl]sulfonyl}aniline, O7T= 6-(3-aminobenzyl)-4-methyl-2-methylsulfinyl-4,6-
dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3- d]pyridazin-5-one, NZT= N-(4-{[4-(pyrazin-2-
yl)piperazin-1-yl]carbonyl}phenyl)quinoline-8-sulfonamide, 1OX=  2-(1H-























b= 145.01  
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α= 69.82  
β= 77.74 
γ= 67.97 
a= 74.63  
b= 80.71  
c= 107.60 
2.50 








3GR4 ADP, DYY*, F-1,6-BP, TLA P 21 







3H6O D8G*, F-1,6-BP, P 21 




b= 155.69  
c= 101.79 
2.00 
3ME3 3SZ*, F-1,6-BP, sulphate P 21 












α= 90.00  
β= 113.56 
γ= 90.00 
a= 95.05  






















































4JPG 1OX*, F-1,6-BP P 21 









































5.2 Results and discussion 
 
5.2.1 Aims 
The aim of this part of the project was to crystallise and collect x-ray diffraction data for 
human M2PYK cysteine mutants of interest in order to obtain structures for investigation 
of the effect of these point mutations on the conformation of M2PYK. 
 
5.2.2 Crystallisation 
As described in chapter 2, crystals were prepared using the vapour diffusion method and 
the hanging drop technique at 18˚C (M2PYK C358A and M2PYK C424A) or 4˚C 
(M2PYK C358S) against 1ml of well solution. Crystallisation conditions were based on 
those used by Morgan et al. [22]. To prepare the drops, 1.5µl of well solution was mixed 
with 1.5µl of 10 mg/ml protein sample with 5mM of each ligand if applicable. The well 
solution contained 6-16% PEG 3350, 100mM sodium cacodylate (pH6.0), 20mM 
Triethanolamine-HCl buffer (pH7.2), 50mM MgCl2, 100mM KCl. Table 2.3 shows how 
the well solutions were prepared.  
A summary of the conditions in which each of the M2PYK mutant crystals were grown is 
shown in table 5.2. Photos of the crystals that were grown are shown in figure 5.2. It was 
not possible to get a photo of crystals of M2PY C358S because they were grown in the 
cold room where there was no camera available. 
 
 Table 5.2 Summary of crystallisation conditions 
M2PYK mutant Temperature Ligands % PEG 3350 
C358A 18˚C F-1,6-BP, oxalate, ATP 14 
C358S 4˚C F-1,6-BP,oxalate, ATP 12 













Figure 5.2 Photos of M2PYK mutant crystals.  
A. M2PYK C358A.  B. M2PYK C424A  
 
5.2.3 Data collection 
As described in chapter 2, x-ray intensity data was collected at the Diamond synchrotron 
radiation facility in Oxfordshire, United Kingdom on beamline IO2. The data was 
collected from single crystals flash frozen in liquid nitrogen at 100K. Crystals were 
dehydrated by equilibration over a well solution containing a high concentration of PEG-
3350 in order to eliminate the appearance of ice-rings. Summaries of the data collection 
statistics are shown in table 5.4 and table 5.6.  
M2PYK C358S was co-crystallised with F-1,6-BP, oxalate and ATP and diffracted to a 
maximum resolution of 3.10Å (Table 5.4). The crystal has an unusual space group of C2 




has unusually large unit cell dimensions (Table 5.4). The data set has a completeness of 
99.8%. 
M2PYK C424A was also co-crystallised with F-1,6-BP, oxalate and ATP and diffracted 
to a maximum resolution of 2.87Å (Table 5.6). This crystal has the more commonly seen 
space group of P 21 and unit cell dimensions comparable to those of 3SRD (Table 5.6 and 
Table 5.1). This data set has a completeness of 90.5%. 
M2PYK C358A was co-crystallised with F-1,6-BP, oxalate and ATP. The crystal 
obtained diffracted but not sufficiently for any processing.  
An example diffraction image from the M2PYK C424A crystal is shown in figure 5.3. 
 
 









5.2.4 M2PYK C424A structure determination 
As described in chapter 2, the M2PYK C424A structure processed by Xia2 automated 
data reduction system and was then solved by molecular replacement using MolRep [74]. 
The M2PYK structure with PDB ID 3SRD was used as the search model because it has 
the same space group and similar unit cell dimensions (Tables 5.1 and 5.4). The structure 
was then refined using REFMAC5 [75]. The refined structure has an R factor of 18.5 and 
Rfree of 24.1. 
 
5.2.5 M2PYK C358S structure determination 
As described in chapter 2, the M2PYK C358S structure was processed by Xia2 
automated data reduction system. The structure was then solved by molecular 
replacement using MolRep using the AC domains of the M2PYK structure with PDB ID 
3SRH [74]. Because the B domains of the M2PYK C358S structure have very poor 
density they were solved separately. One of the B domains was found by using a B 
domain of M2PYK 3SRH separately in MolRep refinement. The other three B domains 
were placed by finding the corresponding B domains in the rabbit MPYK structure with 
PDB ID 1A49, a holo MPYK structure in which the B domains adopt different 
conformations [138]. The structure was then refined using REFMAC5 [75]. The refined 
structure has an R factor of 23.4 and Rfree of 30.0 
 
Table 5.3 Summary of crystals 
Protein Crystallisation method Ligands Resolution (Å) 
M2PYK C358A co-crystallisation F-1,6-BP, oxalate, ATP n/a 
M2PYK C358S co-crystallisation No ligands 3.10 
M2PYK C424A co-crystallisation F-1,6-BP, oxalate, ATP 2.87 
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Table 5.4 Crystallographic data statistics 
 M2PYK C358S M2PYK C424A 
Spacegroup C 2 2 21 P 21 
Unit cell parameters 
     a (Å) 
     b (Å) 
     c  (Å) 
     α  (˚) 
     β  (˚) 















Wavelength (Å) 0.9795 0.9200 
High resolution limit 3.10 2.87 
Low resolution limit 74.91 49.88 
Rmerge (%) 7.7 9.4 
Completeness 99.8 90.5 
Anomolous completeness 96.2 83.8 
Multiplicity 4.8 3.5 
Anomolous multiplicity 2.4 1.7 
I/sigma 12.8 8.3 
Reflections Total 244922 153526 




Table 5.5 Refinement statistics  
 M2PYK C358S M2PYK C424A 
Number of reflections  50549 41736 
Resolution range (Å) 67.14 – 3.10 49.88-2.87 
R factor 0.234 0.1815 
Rfree 0.30 0.2397 
Mean B factor (Å
2
) 59.9 33.3 
R.m.s deviation from ideal   
     Bond lengths (Å) 0.0138 0.0112 
     Bond angles (˚) 1.7822 1.5132 
Ramachandran plot (%)   
     Residues in favoured region 87.9 92.3 
     Residues in allowed region 9.3 3.6 





Figure 5.4 Ramachandran plot for M2PYK C424A  
Ramachandran plot for M2PYK C424A refined structure shows that most residues have 
configurations within the favoured or allowed regions.  
 
 
Figure 5.5 Ramachandran plot for M2PYK C358S 
Ramachandran plot for M2PYK C358S refined structure shows that the majority of 
residues have configurations within the favoured or allowed regions. 
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5.2.6 M2PYK C424A mutation is present in structure 
A model of M2PYK WT (PDB code 3SRD) was used to calculate the |Fo-Fc| difference 
electron density map with M2PYK C424A. The difference electron density map clearly 
shows that the mutation has been successful as indicated by strong negative peaks where 




424 ALA 424 ALA 424 ALA 424 ALA
A B C D
 
Figure 5.6 M2PYK C424 was successfully mutated to alanine 
Electron density maps for M2PYK C424A structure showing that the cysteine was 
successfully mutated to alanine in all chains (A, B, C, and D). The electron density map 
was calculated from a model of M2PYK WT (PDB code 3SRD). The |Fo-Fc| difference 
electron density map using the M2PYK WT model (with Cys424) shows strong negative 
peaks corresponding to the “missing” sulfhydryl group in the M2PYK C424A structure. 
 
 
5.2.7 M2PYK C358S mutation is present in structure 
The mutation of cysteine to serine in the M2PYK C358S is much more subtle than the 
mutation of cysteine to alanine in the M2PYK C424A mutant. At a resolution of only 
3.1Å it is not possible to detect the density difference between a sulphur atom and an 
oxygen atom. However, comparison of the B factors in the structure refined with cysteine 
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in position 358 and those in the structure refined with serine in position 358 gives a good 
indication of which atom (sulphur or oxygen) is the best fit to the electron density 
measured. In the usual case, it would be expected that all the atoms of the same residue 
would have similar B factors. When the M2PYK C358S structure is refined with cysteine 
in position 358 then the B factor of the sulphur atom is much higher than those of the 
other atoms in the residue suggesting that this atom is not a good fit to the electron 
density measured (Table 5.6). Replacement of the cysteine with a serine followed by 
another refinement step shows that the oxygen atom of the serine has a B factor very 
similar to those of the other atoms in the residue showing that the oxygen atom is a good 
fit to the electron density measured (Table 5.6). In this way it can be shown that the 
M2PYK C358S mutation has been successful. 
 
Table 5.6 Comparison of B factors of atoms in residue 358 in each chain of M2PYK 





Chain A Chain B Chain C Chain D 
Cys358 Ser358 Cys358 Ser358 Cys358 Ser358 Cys358 Ser358 
N 79.8 75.7 90.3 84.1 77.0 77.2 48.2 45.3 
CA 82.4 78.5 87.9 80.1 77.2 76.4 50.1 45.0 
C 88.4 85.5 93.8 89.3 78.1 75.9 47.7 44.9 
O 83.2 78.6 92.2 89.2 75.3 71.4 46.3 43.5 
CB 85.1 78.1 86.7 77.0 84.4 80.9 54.0 46.5 
S/O 103.5 81.0 111.7 83.3 95.3 78.4 82.8 54.6 
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5.2.8 Comparison of M2PYK C424A structure to M2PYK WT 
The overall fold of the M2PYK mutant structure is similar to that of the wild type 
enzyme structure. The structural architecture of wild type M2PYK was briefly introduced 
in chapter 1 and was first described by Dombraukas et al. [139]. M2PYK is a tetrameric 
enzyme with each monomer consisting of four domains that are named A, B, C, and N 
(Figure 1.4). The tetramer is described as being a dimer-of-dimers with the 
intermolecular contacts for the first dimer occurring between the A domains of each 
monomer, and tetramerisation occurring via dimerisation along the C domain surfaces of 
each dimer [139] (Figure 1.5). The A-domain contains a α8/β8 barrel and the mobile B 
domain consists of a combination of β sheets and random coils [139]. The active site is 
situated in a cleft between the A and B domains [139] (Figure 1.5). The F-1,6-BP binding 
pocket is located entirely within the C-domain, which consists of both α and β structural 
elements [139] (Figure 1.5). 
Superposition of the M2PYK C424A structure with that of the M2PYK WT holo 
structure (PDB code 3SRD) results in an overall RMS deviation of 0.57Å. The maximum 
displacement between M2PYK WT holo and M2PYK C424A is 3Å which occurs at 
around residue 126 on each of the four chains (Figure 5.7A). This difference is caused by 
the B domain of the M2PYK C424A structure adopting a slightly more closed orientation 
than in the M2PYK WT structure, although this difference is probably not significant 
given the highly flexible nature of the B domain (figure 5.7A). The structure around the 
mutated residue at the C-C interface also shows very little changes (Figure 5.7B). It is 
remarkable that a mutation which has such a significant effect on enzymatic activity has 
such a negligible effect on overall protein structure. One possible explanation for the 
activity loss could be that the mutation results in a more rigid structure. Such a 
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phenomenon can be observed when comparing thermophilic enzymes to mesophilic 
enzymes. Although the structure and architecture of thermophilic enzymes are generally 
highly homologous to their mesophilic counterparts, they have much lower activity at the  
lower temperatures at which most related enzymes are fully active due to their increased 







Figure 5.7 Alignment of M2PYK WT and M2PYK C424A structures.  
A. Superimposed monomers of M2PYK WT (PDB code 3SRD) and M2PYK C424A 
showing that there is not significant change in B domain position as a result of the 
mutation. B. Enlarged view of area around mutated residue of chain A showing that there 





5.2.9 Comparison of M2PYK C358S structure to M2PYK WT 
The most noticeable difference between the M2PYK WT structure and the M2PYK 




-oxalate in the M2PYK C358S active 
site whereas there is only Mg
2+
-oxalate bound in the M2PYK structure (PDB ID: 3SRD). 
In fact, the M2PYK C358S structure is the only human muscle PYK structure with ATP 
in the active site even though others have been crystallised with ATP present (e.g. 
M2PYK C424A, Dombrauckas). The only other mammalian PYKs with ATP in the 
active site is rabbit muscle PYK (PDB ID: 1A49) and human liver PYK with mutation 
C436M (PDB ID: 4IMA). It is interesting that the only other human PYK structure with 
ATP in the active site is also a cysteine point mutant. 
Structural alignment of the M2PYK C358S structure with the M2PYK WT structure 
(PDB ID: 3SRH) results in an overall RMS deviation of about 0.6 Å, which shows that 
the structures are very similar. The biggest variation in structure is in the position of the 
B domain; M2PYK C358S B domain is in a more closed position than the M2PYK WT B 
domain due to the presence of ATP in the M2PYK C358S active site (Figure 5.8, top). A 
closer comparison around the mutated residue shows that there are no significant changes 
in backbone conformation, however as a consequence of the low resolution of the 
M2PYK C358S structure it is not possible to analyse the significance of any changes in 
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Figure 5.8 Alignment of M2PYK WT and M2PYK C358S structures.  
Top. M2PYK WT (PDB code 3SRH) and M2PYK C358S superimposed tetramers; 
M2PYK WT = green, M2PYK C358S = cyan. Bottom. Enlarged view of area around 
mutated residue for each of the chains A, B, C and D. This shows that there are only 
minor differences in side-chain positions as a result of mutation, however the low 
resolution of the M2PYK C358S structure means it is not possible to analyse the 




5.2.10 Differences in ATP binding within the M2PYK C358S tetramer 
Figure 5.9 shows the electron density maps of the three active sites of M2PYK C358S 
that show density for ATP. The density for ATP in the active sites of chains A and C is 
poor, especially around the adenine ring portions, suggesting that these active sites are 
either partially occupied by ATP or that the adenine ring portions are flexible. The 
electron density for ATP in the active site of chain D is much stronger. The stronger 
electron density for ATP in chain D correlates with a much more complete electron 
density map for the B domain of that chain indicating that ATP binding holds the B 
domain in a more rigid closed conformation. The weaker electron density for ATP in 
chains A and C correlates with a less complete electron density map for the B domains of 
these chains indicating that some of the tetramers in the crystal have ATP bound in these 
chains with the B domain in the closed conformation, whereas other tetramers do not 
have ATP bound in these chains so the B domains are in a more flexible, open 
conformation.  
Comparison of the electron density maps indicates that chain A has the least ATP 
density, chain D has the most ATP density and chain C has ATP density between that of 
chain A and chain D (Figure 5.9). The naming of the chains in the tetramer is according 
to the scheme shown in Figure 5.10; chain D is top left, chain A is top right, chain B is 
bottom left and chain C is bottom right. An interesting observation is that the chains with 
strongest ATP electron density (chains D and C) are diagonally related, and so are the 
chains with weakest or no ATP density (chains A and B). This pattern indicates negative 
cooperativity of ATP binding; binding of ATP to one chain inhibits ATP binding to 
adjacent chains. Negative cooperativity of ATP binding has been observed in other 
enzymes, the most well studied of which is the GroEL chaperonin. GroEL is a large 
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protein composed of two rings each made up of seven identical subunits. The rings 
enclose a central cavity in which the denatured protein substrate is bound. During 
chaperone function large conformational changes occur in each of the two rings. Within 
the same ring there is positive cooperativity of ATP binding and hydrolysis but between 
the rings negative cooperativity has been observed [140]. Other examples of enzymes 
exhibiting negative cooperativity of ATP binding include the ATP-dependent protease 
HsIU-HsIV from E.coli [141], the Na,K-ATPase from pig kidney [142], and the F1-








Figure 5.9 Electron density maps of active sites of chains A, C, and D of M2PYK 
C358S.  
The electron density map was calculated from a model of M2PYK WT (PDB code 
3SRH). The density maps are all shown using the same map contour level of 0.2583 
electrons/Å
3
 and illustrate either that chains A and C are only partially occupied by ATP 
or that the adenine rings portions of the ATP molecules are flexible in these chains. Chain 
D has good density for the whole ATP molecule and B domain suggesting that the chain 
D active site is fully occupied and the B domain is more rigid. Chain B is not shown 





5.2.11 Comparison of M2PYK C358S structure to rabbit M1PYK 
 The pattern of ATP binding and varying B domain flexibility seen in M2PYK C358S is 
similar to that seen in the rabbit M1PYK structure with ATP bound (PDB ID 
1A49)[138]. One of the B domains in the M2PYK C358S structure is disordered and 
highly flexible with no ligands in the active site, and this B domain corresponds to the 
same B domain in the rabbit M1PYK tetramer which has been modelled in the open 
conformation and has no ATP bound in the active site (Figure 5.11). Although the B 
domain of chain B of M2PYK C358S has been modelled in the closed conformation, the 
electron density map is very poor so it is likely that this B domain is adopting many 
different conformations (Figure 5.11). The fact that a similar pattern of ATP binding is 
seen in both of these muscle PYK structures indicates that it may be a common feature 
shared between muscle PYKs.  
The binding mode of ATP in the active site of M2PYK C358S almost identical to the  
binding of ATP in rabbit M1PYK [138]. In particular, two of the residues from the B 
domain move into position to interact with the Mg
2+
-ATP; Lys206 interacts with the 
hydroxyls of the ribose moiety, and Arg119 hydrogen bonds to the β phosphate of the 
ATP molecule [138]. In this way the B domain is held in a closed position when ATP is 

















Figure 5.10 Comparison of M2PYK C358S and rabbit M1PYK structures.  
A. Rabbit M1PYK (PDB code 1A49) and M2PYK C358S superimposed tetramers; rabbit 
M1PYK = magenta, M2PYK C358S = cyan. B. View of chain B to show orientations of 
B domains. In M2PYK C358S there a no ligands in the active site, in rabbit muscle PYK 
(1A49) there is only Mg
2+
-oxalate. Although the M2PYK C358S B domain has been 
modelled in a closed conformation, the electron density for this domain is so poor that it 
is hard to tell what position it is in. The fact that the same pattern of three occupied active 
sites per tetramer is seen in both of these muscle PYK structures, despite the space group 




5.2.12 M2PYK C358S structure has an unusual B factor distribution 
The B factor distribution in the M2PYK C358S tetramer is shown in figure 5.11A in 
comparison to M2PYK WT (figure 5.11B), M2PYK C424A (figure 5.11C) and rabbit 
M1PYK (5.11D). It can be seen in figure 5.11A that chain D of the M2PYK C358S 
tetramer has much lower B factors than the other three chains indicating that this chain is 
much more rigid than the other three. Chain D is also the chain with the strongest 
electron density for ATP in the active site and the most complete electron density for the 
B domain (Figure 5.9). The other two human M2PYK structures in figure 5.11 have a 
much more symmetrical distribution of B factors. The rabbit M1PYK structure has also 
been included in figure 5.11 to show the B factor distribution in another MPYK structure 
that has ATP bound in the active site. The rabbit M1PYK shows quite an even B factor 
distribution throughout the tetramer suggesting that the B factor distribution seen in the 
M2PYK C358S structure is a unique feature of this mutant. 
An interesting possibility to consider is that the mutation of Cys358 to serine somehow 
inhibits communication between the chains in the tetramer thereby hindering 
cooperativity and this could be a possible explanation for the lower activity of this 
mutant. This characteristic of the M2PYK C358S structure could be further investigated 
using molecular dynamics which may yield some interesting information about the 
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Figure 5.11 B factor distribution in M2PYK C358S tetramer.  
Blue = low B factor, Red = high B factor A. M2PYK C358S tetramer showing that chain 
D has very low B factors while all other chains have much higher B factors (B factor 
range 50-70). B. M2PYK WT tetramer (PDB ID: 3SRD) showing a much more 
symmetrical B factor distribution. (B factor range 50-70). C. M2PYK C424A tetramer 
also shows a more symmetrical distribution of B factors (B factor range 50-70)  D. Rabbit 
M1PYK tetramer with ATP in active site (PDB ID: 1A49) has much lower B factors 




5.2.13 How do the cysteine point mutations affect stability and activity of M2PYK? 
The only difference between the M2PYK point mutants and the wild type enzyme is a 
change in one amino acid, so it follows that the differences in interactions with amino 
acids neighouring the one that has been changed must determine the observed differences 
in activity, melting temperature and tetramer:dimer:monomer equilibrium. 
Table 5.7 shows the residues that are in close proximity to residue 358 in both M2PYK 
WT and M2PYK C358S.  The distances between the side-chain sulphur or oxygen atom 
and closest atom of the neighbouring residue is also shown along with the type of 
interaction that it likely to occur. Given the hydrophobic nature of cysteine, it could form 
van der Waals interactions with the hydrophobic side-chains of I48 and L465 which are 
3.8Å and 4.7Å away from C358 respectively (Table 5.7). When the cysteine is replaced 
with serine in M2PYK C358S, these van der Waals interactions would not occur. In 
M2PYK WT, C358 could also be a hydrogen bond donor to the backbone carbonyl of 
H464. However, in the mutant, the oxygen of S358 is too far away (6.3Å) from the 
carbonyl oxygen of H464 for a hydrogen bond to be possible. Another notable difference 
is that S358 in the mutant structure could be in hydrogen bonding distance to the 
backbone carbonyl oxygen of V324 (3.5Å), whereas C358 in the WT structure is not 
(Table 5.7). The changes in interactions between these few residues could lead to slight 
conformational changes throughout the protein that lead to weaker interactions, and 




Table 5.7 Closest contacts to M2PYK residue 358 in WT (PDB ID: 3SRD) and C358S 
structures. When residue 358 is interacting with the side chain of a neighbouring amino 
acid, the distance to the nearest atom of that side-chain is stated. Carbonyl signifies that 
the interaction is with the oxygen atom of the backbone carbonyl group of the named 
residue. 
Residue 
Distance from residue 358 side-
chain S/O atom (Å) 
Hydrogen bond 
interaction 
Van der Waals 
interaction 
M2PYK WT M2PYK C358S WT C358S WT C358S 
I48 
Side-chain 
3.8 4.0 - - Yes No 
V324 
Carbonyl 
5.0 3.5 No Maybe - - 
H464 
Carbonyl 
3.3 6.3 Yes No - - 
L465 
Side-chain 
4.7 4.2 - - Yes No 
 
 
There are only two residues that are in close proximity to residue 424 of M2PYK and 
these are shown in Table 5.8. The distances between the side-chain sulphur or carbon 
atom and closest atom of the neighbouring residue is also shown. These very small 
differences distances and interactions are consistent with the thermal denaturation results 
presented in chapter 3 which show that M2PYK C424A has melting behaviour very 
similar to M2PYK WT (Table 3.3). However, it was also found that M2PYK C424A has 
reduced activity compared to M2PYK WT (Table 3.2 and Figure 3.17) and this may be 
due to the much larger distance between A424 and L18 in the mutant, and C424 and L18 
in M2PYK WT (Table 5.8). In M2PYK, it may be possible for C424 to interact with L18 
by van der Waals forces, however the distance is too large (6.6Å) for A424 and L18 to 




Table 5.8 Closest contacts to M2PYK residue 424 in WT (PDB ID: 3SRH) and C424A 
structures. Both of these interactions are between the side-chains of the residues and the 
distances are to the nearest atom of the side-chains of the named residues. 
Residue 
Distance from residue 424 side-
chain S/C atom (Å) 
Van der Waals interaction 
M2PYK WT M2PYK C424A M2PYK WT M2PYK C424A 
I404  
(adjacent chain) 
4.6 4.0 Yes Yes 
L18  
(same chain) 




5.3 Conclusions   
Crystals of M2PYK C424A, M2PYK C358A and M2PYK C358S were grown and from 
these the structures of M2PYK C424A and M2PYK C358S have been solved and refined 
to 2.87Å and 3.10Å respectively. This resolution was good enough to analyse what 
affect, if any, the cysteine point mutations had on the overall conformation of the 
tetramer. 
Comparison of the M2PYK C424A structure containing oxalate, Mg
2+
, and F-1,6-BP to 
the M2PYK WT holo structure with the same ligands (PDB ID: 3SRD) reveals that there 
are no significant changes in the overall conformation of the tetramer as a result of the 
point mutation. A closer look at the region around the mutation at the C-C interface also 
shows no significant differences that could explain the differences in activity and thermal 
stability described in Chapter 3. This is surprising given that the activity of M2PYK 
C424A in the presence of F-1,6-BP is significantly lower than that of M2PYK WT with 
F-1,6-BP (Figure 3.17). It could be that the changes are too subtle to observe in such a 
low resolution structure, but it is fascinating that there are apparently no structural 
changes as a result of a point mutation that has such significant effect on activity. 
The M2PYK C358S structure contained oxalate, Mg
2+
, ATP and F-1,6-BP. The presence 
of ATP in the active site is an interesting feature in itself due to the fact that there are no 
other structures of mammalian M2PYK with ATP in the active site, even when ATP was 
included in the crystallization drop. There is, however, one structure of rabbit M1PYK 
with ATP in the active site. When the M2PYK C358S structure is compared to M2PYK 
WT containing oxalate, Mg
2+
 and F-1,6-BP the main difference can be seen in the 
conformation of the B domain. In the M2PYK C358S structure the B domains are in a 
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more closed position than in the M2PYK WT structure and this is probably due to the 
presence of ATP in the M2PYK C358S structure. Another major difference that can be 
seen between the two structures is in the distribution of B factors within the tetramers. 
Although the B factors cannot be directly compared between the structures, the difference 
in the distribution of the low and high B factor regions within each of the tetramers is 
intriguing and could give some insight into the mechanism of enzyme cooperativity 
within the M2PYK tetramer (Figure 5.11). It could be that mutating Cys358 to serine 
somehow inhibits some structural or energetic transmission through the M2PYK tetramer 
thereby hindering cooperativity. If this is true, then it could be an important contributing 
factor to the decreased activity and thermal stability of the M2PYK C358S mutant.  
A comparison of the M2PYK C358S structure with the only other muscle PYK in the 
PDB with ATP in the active site, rabbit M1PYK, shows that they share the same pattern 
of ATP binding. In both structures, only three of the chains have ATP in the active site. 
Furthermore, in both structures the different B domains of the same structure adopt 
different conformations. Although this feature cannot be seen in the model of M2PYK 
C358S, analysis of the electron density of the B domains show that they have very 
different levels of completeness indicating varying degrees of flexibility. Comparison of 
the B factor distributions of these two structures, the only two muscle PYK structures 
with ATP in the active site, shows that the unusual B factor distribution observed in the 




Chapter 6: Summary and future work 
 
6.1 Open Questions 
- How is M2PYK regulated by oxidation? 
- How is M1PYK protected from oxidation? 
- What is the effect of M2PYK oxidation in vivo? 
 
6.2 Major findings and future work 
6.2.1 How is M2PYK regulated by oxidation? 
Evidence has been presented in this thesis that shows that oxidation by H2O2 decreases 
M2PYK thermal stability and activity, although none of the cysteine point mutants tested 
resulted in protection from oxidising effects. This indicates that either there is a different 
cysteine involved or it is oxidation of a combination of cysteines that regulates M2PYK 
activity. In order to clarify which cysteines are oxidised in M2PYK it may be possible to 
identify oxidised cysteines by mass spectrometry, however this is extremely challenging 
due to the transient nature of cysteine oxidation. Furthermore, special precautions need to 
be taken throughout sample preparation to ensure that the samples are not exposed to 
oxidising conditions during processing.  
It has also been demonstrated here that M2PYK is modified by S-nitrosylation. However, 
it is still unclear which cysteine(s) is modified. Although mutation of Cys358 resulted in 
an almost complete loss of S-nitrosylation, it is likely that this effect is due to the 
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conformational changes caused by the mutation that result in M2PYK being stabilized in 
the tetrameric form. Analysis of the protein samples that had undergone S-nitrosylation 
followed by biotin-switch identified Csy326 as being modified, a cysteine that has been 
identified in another study as being S-nitrosylated [137]. Interestingly, mutation of 
Cys326 to serine results in M2PYK that is unable to form tetramers indicating that 
modification of this cysteine could play an important role in regulation of M2PYK 
activity.  
Following on from this, it would be interesting to find out the effect of oxidation by H2O2 
and S-nitrosylation on M2PYK oligomeric state using analytical gel filtration. The 
expected result would be that oxidation causes M2PYK to become more monomeric, thus 
inactivating the enzyme. This is based on results the results from Cantley’s group which 
show that after cells are treated with oxidizing agent, Flag tagged M2PYK no longer co-
precipitated with endogenous M2PYK indicating that M2PYK could not form oligomers 
in oxidizing conditions [34].  
Another form of oxidation that has not been considered in this thesis, but could be 
involved in the regulation of M2PYK, is S-glutathionylation. S-glutathionylation 
involves the addition of GSH (γ-glutamylcysteinylglycine) to cysteine residues and acts 
both to protect and modify protein structure and function. In a proteomic study carried 
out to identify the glutathionylome of Plasomodium falciparum, pyruvate kinase was 
among the 493 targets of S-glutathionylation identified [144]. It would be interesting to 
carry out M2PYK activity assays in the presence of GSH and also analyse the effect of 
GSH on M2PYK oligomeric state. It would also be possible to detect which cysteines are 
modified using mass spectrometry. M2PYK could also be crystallised in the presence of 




6.2.2 How is M1PYK protected from oxidation? 
In this thesis it has been shown that M1PYK thermal stability and activity are mostly 
unaffected by oxidising conditions, whereas M2PYK stability and activity are 
significantly decreased (Figure 3.16). Understanding how M1PYK is protected from 
oxidation could give valuable information about how M2PYK is modified. One major 
difference between the two isoforms is that M1PYK is constitutively in the active 
tetrameric T-state, whereas M2PYK shifts between inactive monomer/dimer and 
tetrameric states in a dynamic equilibrium. Therefore, one possibility is that the 
tetrameric nature of M1PYK protects those cysteines that are susceptible to oxidation due 
to their location on the tetramerisation interfaces. In M2PYK these same cysteines would 
be exposed to the solvent as M2PYK constantly changes its oligomeric state. One way to 
test this hypothesis would be to add the allosteric activator F-1,6-BP to M2PYK before 
testing the effect of oxidation on stability and enzyme activity. F-1,6-BP would lock 
M2PYK in the active tetrameric state and should therefore  prevent oxidation of cysteines 
located on the interfaces. 
Another key difference between M1- and M2PYK is that M1PYK lacks one of the 
cysteines present in M2PYK, C424, and has a leucine in its place. It is conceivable then 
that this cysteine is the key cysteine that is involved in the regulation of M2PYK by 
oxidation. However, it has been shown in this study that mutation of this cysteine in 
M2PYK to the M1PYK equivalent residue, leucine, is not sufficient to protect M2PYK 






6.2.3 What is the effect of M2PYK oxidation/S-nitrosylation in vivo? 
It is clear from the work presented here together with the work of others that M2PYK is 
subject to oxidation/S-nitrosylation of at least some of its cysteine residues (Figure 
4.5)[34][128][129][130]. An important next step would be to investigate the significance 
of these modifications in vivo.  In order to specifically assess the changes caused by 
M2PYK modifications it is necessary to eliminate any influence that could be attributed 
to M1PYK. Work is already underway in our laboratory to use CRISPR (Clustered, 
Regularly Interspaced, Short Palindromic Repeat) technology to knock out the PKM gene 
in a human cancer cell line to allow for selective expression of either M1- or M2PYK 
[145]. These cell lines can then be treated with oxidising or nitrosylating agents and the 
effect on cell growth and proliferation measured. The M2PYK cysteine point mutants 
already developed can also be used to see how these mutants may change the cellular 
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